6	TRULICITY.xml:S1:4:1	O
ADVERSE	TRULICITY.xml:S1:6:7	O
REACTIONS	TRULICITY.xml:S1:14:9	O

The	TRULICITY.xml:S1:27:3	O
following	TRULICITY.xml:S1:31:9	O
serious	TRULICITY.xml:S1:41:7	O
reactions	TRULICITY.xml:S1:49:9	O
are	TRULICITY.xml:S1:59:3	O
described	TRULICITY.xml:S1:63:9	O
below	TRULICITY.xml:S1:73:5	O
or	TRULICITY.xml:S1:79:2	O
elsewhere	TRULICITY.xml:S1:82:9	O
in	TRULICITY.xml:S1:92:2	O
the	TRULICITY.xml:S1:95:3	O
prescribing	TRULICITY.xml:S1:99:11	O
information	TRULICITY.xml:S1:111:11	O
:	TRULICITY.xml:S1:122:1	O

Risk	TRULICITY.xml:S1:131:4	B-Factor
of	TRULICITY.xml:S1:136:2	O
Thyroid	TRULICITY.xml:S1:139:7	B-AdverseReaction
C	TRULICITY.xml:S1:147:1	I-AdverseReaction
-	TRULICITY.xml:S1:148:1	I-AdverseReaction
cell	TRULICITY.xml:S1:149:4	I-AdverseReaction
Tumors	TRULICITY.xml:S1:154:6	I-AdverseReaction
[	TRULICITY.xml:S1:161:1	O
see	TRULICITY.xml:S1:162:3	O
Warnings	TRULICITY.xml:S1:166:8	O
and	TRULICITY.xml:S1:175:3	O
Precautions	TRULICITY.xml:S1:179:11	O
(	TRULICITY.xml:S1:191:1	O
5.1	TRULICITY.xml:S1:194:3	O
)]	TRULICITY.xml:S1:199:2	O

Pancreatitis	TRULICITY.xml:S1:208:12	B-AdverseReaction
[	TRULICITY.xml:S1:221:1	O
see	TRULICITY.xml:S1:222:3	O
Warnings	TRULICITY.xml:S1:226:8	O
and	TRULICITY.xml:S1:235:3	O
Precautions	TRULICITY.xml:S1:239:11	O
(	TRULICITY.xml:S1:251:1	O
5.2	TRULICITY.xml:S1:254:3	O
)]	TRULICITY.xml:S1:259:2	O

Hypoglycemia	TRULICITY.xml:S1:268:12	B-AdverseReaction
with	TRULICITY.xml:S1:281:4	O
Concomitant	TRULICITY.xml:S1:286:11	O
Use	TRULICITY.xml:S1:298:3	O
of	TRULICITY.xml:S1:302:2	O
Insulin	TRULICITY.xml:S1:305:7	O
Secretagogues	TRULICITY.xml:S1:313:13	O
or	TRULICITY.xml:S1:327:2	O
Insulin	TRULICITY.xml:S1:330:7	O
[	TRULICITY.xml:S1:338:1	O
see	TRULICITY.xml:S1:339:3	O
Warnings	TRULICITY.xml:S1:343:8	O
and	TRULICITY.xml:S1:352:3	O
Precautions	TRULICITY.xml:S1:356:11	O
(	TRULICITY.xml:S1:368:1	O
5.3	TRULICITY.xml:S1:371:3	O
)]	TRULICITY.xml:S1:376:2	O

Hypersensitivity	TRULICITY.xml:S1:385:16	B-AdverseReaction
reactions	TRULICITY.xml:S1:402:9	O
[	TRULICITY.xml:S1:412:1	O
see	TRULICITY.xml:S1:413:3	O
Warnings	TRULICITY.xml:S1:417:8	O
and	TRULICITY.xml:S1:426:3	O
Precautions	TRULICITY.xml:S1:430:11	O
(	TRULICITY.xml:S1:442:1	O
5.4	TRULICITY.xml:S1:445:3	O
)]	TRULICITY.xml:S1:450:2	O

Renal	TRULICITY.xml:S1:459:5	B-AdverseReaction
impairment	TRULICITY.xml:S1:465:10	I-AdverseReaction
[	TRULICITY.xml:S1:476:1	O
see	TRULICITY.xml:S1:477:3	O
Warnings	TRULICITY.xml:S1:481:8	O
and	TRULICITY.xml:S1:490:3	O
Precautions	TRULICITY.xml:S1:494:11	O
(	TRULICITY.xml:S1:506:1	O
5.5	TRULICITY.xml:S1:509:3	O
)]	TRULICITY.xml:S1:514:2	O

Severe	TRULICITY.xml:S1:523:6	B-Severity
Gastrointestinal	TRULICITY.xml:S1:530:16	B-AdverseReaction
Disease	TRULICITY.xml:S1:547:7	I-AdverseReaction
[	TRULICITY.xml:S1:555:1	O
see	TRULICITY.xml:S1:556:3	O
Warnings	TRULICITY.xml:S1:560:8	O
and	TRULICITY.xml:S1:569:3	O
Precautions	TRULICITY.xml:S1:573:11	O
(	TRULICITY.xml:S1:585:1	O
5.6	TRULICITY.xml:S1:588:3	O
)]	TRULICITY.xml:S1:593:2	O

EXCERPT	TRULICITY.xml:S1:604:7	O
:	TRULICITY.xml:S1:611:1	O
The	TRULICITY.xml:S1:615:3	O
most	TRULICITY.xml:S1:619:4	O
common	TRULICITY.xml:S1:624:6	O
adverse	TRULICITY.xml:S1:631:7	O
reactions	TRULICITY.xml:S1:639:9	O
,	TRULICITY.xml:S1:648:1	O
reported	TRULICITY.xml:S1:650:8	O
in	TRULICITY.xml:S1:659:2	O
5%	TRULICITY.xml:S1:664:2	O
of	TRULICITY.xml:S1:667:2	O
patients	TRULICITY.xml:S1:670:8	O
treated	TRULICITY.xml:S1:679:7	O
with	TRULICITY.xml:S1:687:4	O
TRULICITY	TRULICITY.xml:S1:692:9	O
are	TRULICITY.xml:S1:702:3	O
:	TRULICITY.xml:S1:705:1	O
nausea	TRULICITY.xml:S1:707:6	B-AdverseReaction
,	TRULICITY.xml:S1:713:1	O
diarrhea	TRULICITY.xml:S1:715:8	B-AdverseReaction
,	TRULICITY.xml:S1:723:1	O
vomiting	TRULICITY.xml:S1:725:8	B-AdverseReaction
,	TRULICITY.xml:S1:733:1	O
abdominal	TRULICITY.xml:S1:735:9	B-AdverseReaction
pain	TRULICITY.xml:S1:745:4	I-AdverseReaction
,	TRULICITY.xml:S1:749:1	O
and	TRULICITY.xml:S1:751:3	O
decreased	TRULICITY.xml:S1:755:9	B-AdverseReaction
appetite	TRULICITY.xml:S1:765:8	I-AdverseReaction
(	TRULICITY.xml:S1:774:1	O
6.1	TRULICITY.xml:S1:777:3	O
)	TRULICITY.xml:S1:782:1	O
.	TRULICITY.xml:S1:783:1	O

To	TRULICITY.xml:S1:791:2	O

report	TRULICITY.xml:S1:794:6	O
SUSPECTED	TRULICITY.xml:S1:801:9	O
ADVERSE	TRULICITY.xml:S1:811:7	O
REACTIONS	TRULICITY.xml:S1:819:9	O
,	TRULICITY.xml:S1:828:1	O
contact	TRULICITY.xml:S1:830:7	O
Eli	TRULICITY.xml:S1:838:3	O
Lilly	TRULICITY.xml:S1:842:5	O
and	TRULICITY.xml:S1:848:3	O
Company	TRULICITY.xml:S1:852:7	O
at	TRULICITY.xml:S1:860:2	O
1	TRULICITY.xml:S1:863:1	O
-	TRULICITY.xml:S1:864:1	O
800	TRULICITY.xml:S1:865:3	O
-	TRULICITY.xml:S1:868:1	O
LillyRx	TRULICITY.xml:S1:869:7	O
(	TRULICITY.xml:S1:877:1	O
1	TRULICITY.xml:S1:878:1	O
-	TRULICITY.xml:S1:879:1	O
800	TRULICITY.xml:S1:880:3	O
-	TRULICITY.xml:S1:883:1	O
545	TRULICITY.xml:S1:884:3	O
-	TRULICITY.xml:S1:887:1	O
5979	TRULICITY.xml:S1:888:4	O
)	TRULICITY.xml:S1:892:1	O
or	TRULICITY.xml:S1:894:2	O
FDA	TRULICITY.xml:S1:897:3	O
at	TRULICITY.xml:S1:901:2	O
1	TRULICITY.xml:S1:904:1	O
-	TRULICITY.xml:S1:905:1	O
800	TRULICITY.xml:S1:906:3	O
-	TRULICITY.xml:S1:909:1	O
FDA	TRULICITY.xml:S1:910:3	O
-	TRULICITY.xml:S1:913:1	O
1088	TRULICITY.xml:S1:914:4	O
or	TRULICITY.xml:S1:919:2	O
www	TRULICITY.xml:S1:922:3	O
.	TRULICITY.xml:S1:925:1	O
fda	TRULICITY.xml:S1:926:3	O
.	TRULICITY.xml:S1:929:1	O
gov	TRULICITY.xml:S1:930:3	O
medwatch	TRULICITY.xml:S1:934:8	O
.	TRULICITY.xml:S1:942:1	O

6.1	TRULICITY.xml:S1:954:3	O

Clinical	TRULICITY.xml:S1:958:8	O
Studies	TRULICITY.xml:S1:967:7	O
Experience	TRULICITY.xml:S1:975:10	O

Because	TRULICITY.xml:S1:989:7	O
clinical	TRULICITY.xml:S1:997:8	O
studies	TRULICITY.xml:S1:1006:7	O
are	TRULICITY.xml:S1:1014:3	O
conducted	TRULICITY.xml:S1:1018:9	O
under	TRULICITY.xml:S1:1028:5	O
widely	TRULICITY.xml:S1:1034:6	O
varying	TRULICITY.xml:S1:1041:7	O
conditions	TRULICITY.xml:S1:1049:10	O
,	TRULICITY.xml:S1:1059:1	O
adverse	TRULICITY.xml:S1:1061:7	O
reaction	TRULICITY.xml:S1:1069:8	O
rates	TRULICITY.xml:S1:1078:5	O
observed	TRULICITY.xml:S1:1084:8	O
in	TRULICITY.xml:S1:1093:2	O
the	TRULICITY.xml:S1:1096:3	O
clinical	TRULICITY.xml:S1:1100:8	O
studies	TRULICITY.xml:S1:1109:7	O
of	TRULICITY.xml:S1:1117:2	O
a	TRULICITY.xml:S1:1120:1	O
drug	TRULICITY.xml:S1:1122:4	O
cannot	TRULICITY.xml:S1:1127:6	O
be	TRULICITY.xml:S1:1134:2	O
directly	TRULICITY.xml:S1:1137:8	O
compared	TRULICITY.xml:S1:1146:8	O
to	TRULICITY.xml:S1:1155:2	O
rates	TRULICITY.xml:S1:1158:5	O
in	TRULICITY.xml:S1:1164:2	O
the	TRULICITY.xml:S1:1167:3	O
clinical	TRULICITY.xml:S1:1171:8	O
studies	TRULICITY.xml:S1:1180:7	O
of	TRULICITY.xml:S1:1188:2	O
another	TRULICITY.xml:S1:1191:7	O
drug	TRULICITY.xml:S1:1199:4	O
and	TRULICITY.xml:S1:1204:3	O
may	TRULICITY.xml:S1:1208:3	O
not	TRULICITY.xml:S1:1212:3	O
reflect	TRULICITY.xml:S1:1216:7	O
the	TRULICITY.xml:S1:1224:3	O
rates	TRULICITY.xml:S1:1228:5	O
observed	TRULICITY.xml:S1:1234:8	O
in	TRULICITY.xml:S1:1243:2	O
practice	TRULICITY.xml:S1:1246:8	O
.	TRULICITY.xml:S1:1254:1	O

Pool	TRULICITY.xml:S1:1264:4	O
of	TRULICITY.xml:S1:1269:2	O
Placebo	TRULICITY.xml:S1:1272:7	O
-	TRULICITY.xml:S1:1279:1	O
controlled	TRULICITY.xml:S1:1280:10	O
Trials	TRULICITY.xml:S1:1291:6	O

The	TRULICITY.xml:S1:1304:3	O
data	TRULICITY.xml:S1:1308:4	O
in	TRULICITY.xml:S1:1313:2	O
Table	TRULICITY.xml:S1:1317:5	O
1	TRULICITY.xml:S1:1323:1	O
are	TRULICITY.xml:S1:1326:3	O
derived	TRULICITY.xml:S1:1330:7	O
from	TRULICITY.xml:S1:1338:4	O
the	TRULICITY.xml:S1:1343:3	O
placebo	TRULICITY.xml:S1:1347:7	O
-	TRULICITY.xml:S1:1354:1	O
controlled	TRULICITY.xml:S1:1355:10	O
trials	TRULICITY.xml:S1:1366:6	O
[	TRULICITY.xml:S1:1374:1	O
see	TRULICITY.xml:S1:1375:3	O
Clinical	TRULICITY.xml:S1:1379:8	O
Studies	TRULICITY.xml:S1:1388:7	O
(	TRULICITY.xml:S1:1396:1	O
14	TRULICITY.xml:S1:1399:2	O
)]	TRULICITY.xml:S1:1403:2	O
.	TRULICITY.xml:S1:1407:1	O

These	TRULICITY.xml:S1:1413:5	O
data	TRULICITY.xml:S1:1419:4	O
reflect	TRULICITY.xml:S1:1424:7	O
exposure	TRULICITY.xml:S1:1432:8	O
of	TRULICITY.xml:S1:1441:2	O
1670	TRULICITY.xml:S1:1444:4	O
patients	TRULICITY.xml:S1:1449:8	O
to	TRULICITY.xml:S1:1458:2	O
TRULICITY	TRULICITY.xml:S1:1461:9	O
and	TRULICITY.xml:S1:1471:3	O
a	TRULICITY.xml:S1:1475:1	O
mean	TRULICITY.xml:S1:1477:4	O
duration	TRULICITY.xml:S1:1482:8	O
of	TRULICITY.xml:S1:1491:2	O
exposure	TRULICITY.xml:S1:1494:8	O
to	TRULICITY.xml:S1:1503:2	O
TRULICITY	TRULICITY.xml:S1:1506:9	O
of	TRULICITY.xml:S1:1516:2	O
23.8	TRULICITY.xml:S1:1519:4	O
weeks	TRULICITY.xml:S1:1524:5	O
.	TRULICITY.xml:S1:1529:1	O

Across	TRULICITY.xml:S1:1531:6	O
the	TRULICITY.xml:S1:1538:3	O
treatment	TRULICITY.xml:S1:1542:9	O
arms	TRULICITY.xml:S1:1552:4	O
,	TRULICITY.xml:S1:1556:1	O
the	TRULICITY.xml:S1:1558:3	O
mean	TRULICITY.xml:S1:1562:4	O
age	TRULICITY.xml:S1:1567:3	O
of	TRULICITY.xml:S1:1571:2	O
patients	TRULICITY.xml:S1:1574:8	O
was	TRULICITY.xml:S1:1583:3	O
56	TRULICITY.xml:S1:1587:2	O
years	TRULICITY.xml:S1:1590:5	O
,	TRULICITY.xml:S1:1595:1	O
1%	TRULICITY.xml:S1:1597:2	O
were	TRULICITY.xml:S1:1600:4	O
75	TRULICITY.xml:S1:1605:2	O
years	TRULICITY.xml:S1:1608:5	O
or	TRULICITY.xml:S1:1614:2	O
older	TRULICITY.xml:S1:1617:5	O
and	TRULICITY.xml:S1:1623:3	O
53%	TRULICITY.xml:S1:1627:3	O
were	TRULICITY.xml:S1:1631:4	O
male	TRULICITY.xml:S1:1636:4	O
.	TRULICITY.xml:S1:1640:1	O

The	TRULICITY.xml:S1:1642:3	O
population	TRULICITY.xml:S1:1646:10	O
in	TRULICITY.xml:S1:1657:2	O
these	TRULICITY.xml:S1:1660:5	O
studies	TRULICITY.xml:S1:1666:7	O
was	TRULICITY.xml:S1:1674:3	O
69%	TRULICITY.xml:S1:1678:3	O
White	TRULICITY.xml:S1:1682:5	O
,	TRULICITY.xml:S1:1687:1	O
7%	TRULICITY.xml:S1:1689:2	O
Black	TRULICITY.xml:S1:1692:5	O
or	TRULICITY.xml:S1:1698:2	O
African	TRULICITY.xml:S1:1701:7	O
American	TRULICITY.xml:S1:1709:8	O
,	TRULICITY.xml:S1:1717:1	O
13%	TRULICITY.xml:S1:1719:3	O
Asian	TRULICITY.xml:S1:1723:5	O
;	TRULICITY.xml:S1:1728:1	O
30%	TRULICITY.xml:S1:1730:3	O
were	TRULICITY.xml:S1:1734:4	O
of	TRULICITY.xml:S1:1739:2	O
Hispanic	TRULICITY.xml:S1:1742:8	O
or	TRULICITY.xml:S1:1751:2	O
Latino	TRULICITY.xml:S1:1754:6	O
ethnicity	TRULICITY.xml:S1:1761:9	O
.	TRULICITY.xml:S1:1770:1	O

At	TRULICITY.xml:S1:1772:2	O
baseline	TRULICITY.xml:S1:1775:8	O
,	TRULICITY.xml:S1:1783:1	O
the	TRULICITY.xml:S1:1785:3	O
population	TRULICITY.xml:S1:1789:10	O
had	TRULICITY.xml:S1:1800:3	O
diabetes	TRULICITY.xml:S1:1804:8	O
for	TRULICITY.xml:S1:1813:3	O
an	TRULICITY.xml:S1:1817:2	O
average	TRULICITY.xml:S1:1820:7	O
of	TRULICITY.xml:S1:1828:2	O
8.0	TRULICITY.xml:S1:1831:3	O
years	TRULICITY.xml:S1:1835:5	O
and	TRULICITY.xml:S1:1841:3	O
had	TRULICITY.xml:S1:1845:3	O
a	TRULICITY.xml:S1:1849:1	O
mean	TRULICITY.xml:S1:1851:4	O
HbA1c	TRULICITY.xml:S1:1856:5	O
of	TRULICITY.xml:S1:1862:2	O
8.0%	TRULICITY.xml:S1:1865:4	O
.	TRULICITY.xml:S1:1869:1	O

At	TRULICITY.xml:S1:1871:2	O
baseline	TRULICITY.xml:S1:1874:8	O
,	TRULICITY.xml:S1:1882:1	O
2.5%	TRULICITY.xml:S1:1884:4	O
of	TRULICITY.xml:S1:1889:2	O
the	TRULICITY.xml:S1:1892:3	O
population	TRULICITY.xml:S1:1896:10	O
reported	TRULICITY.xml:S1:1907:8	O
retinopathy	TRULICITY.xml:S1:1916:11	O
.	TRULICITY.xml:S1:1927:1	O

Baseline	TRULICITY.xml:S1:1929:8	O
estimated	TRULICITY.xml:S1:1938:9	O
renal	TRULICITY.xml:S1:1948:5	O
function	TRULICITY.xml:S1:1954:8	O
was	TRULICITY.xml:S1:1963:3	O
normal	TRULICITY.xml:S1:1967:6	O
or	TRULICITY.xml:S1:1974:2	O
mildly	TRULICITY.xml:S1:1977:6	O
impaired	TRULICITY.xml:S1:1984:8	O
(	TRULICITY.xml:S1:1993:1	O
eGFR	TRULICITY.xml:S1:1994:4	O
60	TRULICITY.xml:S1:2001:2	O
mL	TRULICITY.xml:S1:2003:2	O
min	TRULICITY.xml:S1:2006:3	O
1.73	TRULICITY.xml:S1:2010:4	O
m	TRULICITY.xml:S1:2015:1	O
2	TRULICITY.xml:S1:2018:1	O
)	TRULICITY.xml:S1:2021:1	O
in	TRULICITY.xml:S1:2023:2	O
96.0%	TRULICITY.xml:S1:2026:5	O
of	TRULICITY.xml:S1:2032:2	O
the	TRULICITY.xml:S1:2035:3	O
pooled	TRULICITY.xml:S1:2039:6	O
study	TRULICITY.xml:S1:2046:5	O
populations	TRULICITY.xml:S1:2052:11	O
.	TRULICITY.xml:S1:2063:1	O

Table	TRULICITY.xml:S1:2069:5	O
1	TRULICITY.xml:S1:2075:1	O
shows	TRULICITY.xml:S1:2077:5	O
common	TRULICITY.xml:S1:2083:6	O
adverse	TRULICITY.xml:S1:2090:7	O
reactions	TRULICITY.xml:S1:2098:9	O
,	TRULICITY.xml:S1:2107:1	O
excluding	TRULICITY.xml:S1:2109:9	O
hypoglycemia	TRULICITY.xml:S1:2119:12	B-AdverseReaction
,	TRULICITY.xml:S1:2131:1	O
associated	TRULICITY.xml:S1:2133:10	O
with	TRULICITY.xml:S1:2144:4	O
the	TRULICITY.xml:S1:2149:3	O
use	TRULICITY.xml:S1:2153:3	O
of	TRULICITY.xml:S1:2157:2	O
TRULICITY	TRULICITY.xml:S1:2160:9	O
in	TRULICITY.xml:S1:2170:2	O
the	TRULICITY.xml:S1:2173:3	O
pool	TRULICITY.xml:S1:2177:4	O
of	TRULICITY.xml:S1:2182:2	O
placebo	TRULICITY.xml:S1:2185:7	O
-	TRULICITY.xml:S1:2192:1	O
controlled	TRULICITY.xml:S1:2193:10	O
trials	TRULICITY.xml:S1:2204:6	O
.	TRULICITY.xml:S1:2210:1	O

These	TRULICITY.xml:S1:2212:5	O
adverse	TRULICITY.xml:S1:2218:7	O
reactions	TRULICITY.xml:S1:2226:9	O
were	TRULICITY.xml:S1:2236:4	O
not	TRULICITY.xml:S1:2241:3	O
present	TRULICITY.xml:S1:2245:7	O
at	TRULICITY.xml:S1:2253:2	O
baseline	TRULICITY.xml:S1:2256:8	O
,	TRULICITY.xml:S1:2264:1	O
occurred	TRULICITY.xml:S1:2266:8	O
more	TRULICITY.xml:S1:2275:4	O
commonly	TRULICITY.xml:S1:2280:8	O
on	TRULICITY.xml:S1:2289:2	O
TRULICITY	TRULICITY.xml:S1:2292:9	O
than	TRULICITY.xml:S1:2302:4	O
on	TRULICITY.xml:S1:2307:2	O
placebo	TRULICITY.xml:S1:2310:7	O
,	TRULICITY.xml:S1:2317:1	O
and	TRULICITY.xml:S1:2319:3	O
occurred	TRULICITY.xml:S1:2323:8	O
in	TRULICITY.xml:S1:2332:2	O
at	TRULICITY.xml:S1:2335:2	O
least	TRULICITY.xml:S1:2338:5	O
5%	TRULICITY.xml:S1:2344:2	O
of	TRULICITY.xml:S1:2347:2	O
patients	TRULICITY.xml:S1:2350:8	O
treated	TRULICITY.xml:S1:2359:7	O
with	TRULICITY.xml:S1:2367:4	O
TRULICITY	TRULICITY.xml:S1:2372:9	O
.	TRULICITY.xml:S1:2381:1	O

Table	TRULICITY.xml:S1:2387:5	O
1	TRULICITY.xml:S1:2393:1	O
:	TRULICITY.xml:S1:2394:1	O
Adverse	TRULICITY.xml:S1:2396:7	O
Reactions	TRULICITY.xml:S1:2404:9	O
in	TRULICITY.xml:S1:2414:2	O
Placebo	TRULICITY.xml:S1:2417:7	O
-	TRULICITY.xml:S1:2424:1	O
Controlled	TRULICITY.xml:S1:2425:10	O
Trials	TRULICITY.xml:S1:2436:6	O
Reported	TRULICITY.xml:S1:2443:8	O
in	TRULICITY.xml:S1:2452:2	O
5%	TRULICITY.xml:S1:2457:2	O
of	TRULICITY.xml:S1:2460:2	O
TRULICITY	TRULICITY.xml:S1:2463:9	O
-	TRULICITY.xml:S1:2472:1	O
Treated	TRULICITY.xml:S1:2473:7	O
Patients	TRULICITY.xml:S1:2481:8	O

a	TRULICITY.xml:S1:2493:1	O
Includes	TRULICITY.xml:S1:2495:8	O
diarrhea	TRULICITY.xml:S1:2504:8	B-AdverseReaction
,	TRULICITY.xml:S1:2512:1	O
fecal	TRULICITY.xml:S1:2514:5	B-AdverseReaction
volume	TRULICITY.xml:S1:2520:6	I-AdverseReaction
increased	TRULICITY.xml:S1:2527:9	I-AdverseReaction
,	TRULICITY.xml:S1:2536:1	O
frequent	TRULICITY.xml:S1:2538:8	B-AdverseReaction
bowel	TRULICITY.xml:S1:2547:5	I-AdverseReaction
movements	TRULICITY.xml:S1:2553:9	I-AdverseReaction
.	TRULICITY.xml:S1:2562:1	O

b	TRULICITY.xml:S1:2570:1	O
Includes	TRULICITY.xml:S1:2572:8	O
retching	TRULICITY.xml:S1:2581:8	B-AdverseReaction
,	TRULICITY.xml:S1:2589:1	O
vomiting	TRULICITY.xml:S1:2591:8	B-AdverseReaction
,	TRULICITY.xml:S1:2599:1	O
vomiting	TRULICITY.xml:S1:2601:8	B-AdverseReaction
projectile	TRULICITY.xml:S1:2610:10	I-AdverseReaction
.	TRULICITY.xml:S1:2620:1	O

c	TRULICITY.xml:S1:2628:1	O
Includes	TRULICITY.xml:S1:2630:8	O
abdominal	TRULICITY.xml:S1:2639:9	B-AdverseReaction
discomfort	TRULICITY.xml:S1:2649:10	I-AdverseReaction
,	TRULICITY.xml:S1:2659:1	O
abdominal	TRULICITY.xml:S1:2661:9	B-AdverseReaction
pain	TRULICITY.xml:S1:2671:4	I-AdverseReaction
,	TRULICITY.xml:S1:2675:1	O
abdominal	TRULICITY.xml:S1:2677:9	B-AdverseReaction
pain	TRULICITY.xml:S1:2687:4	I-AdverseReaction
lower	TRULICITY.xml:S1:2692:5	I-AdverseReaction
,	TRULICITY.xml:S1:2697:1	O
abdominal	TRULICITY.xml:S1:2699:9	B-AdverseReaction
pain	TRULICITY.xml:S1:2709:4	I-AdverseReaction
upper	TRULICITY.xml:S1:2714:5	I-AdverseReaction
,	TRULICITY.xml:S1:2719:1	O
abdominal	TRULICITY.xml:S1:2721:9	B-AdverseReaction
tenderness	TRULICITY.xml:S1:2731:10	I-AdverseReaction
,	TRULICITY.xml:S1:2741:1	O
gastrointestinal	TRULICITY.xml:S1:2743:16	B-AdverseReaction
pain	TRULICITY.xml:S1:2760:4	I-AdverseReaction
.	TRULICITY.xml:S1:2764:1	O

d	TRULICITY.xml:S1:2772:1	O
Includes	TRULICITY.xml:S1:2774:8	O
fatigue	TRULICITY.xml:S1:2783:7	B-AdverseReaction
,	TRULICITY.xml:S1:2790:1	O
asthenia	TRULICITY.xml:S1:2792:8	B-AdverseReaction
,	TRULICITY.xml:S1:2800:1	O
malaise	TRULICITY.xml:S1:2802:7	B-AdverseReaction
.	TRULICITY.xml:S1:2809:1	O

Note	TRULICITY.xml:S1:2819:4	O
:	TRULICITY.xml:S1:2823:1	O
Percentages	TRULICITY.xml:S1:2825:11	O
reflect	TRULICITY.xml:S1:2837:7	O
the	TRULICITY.xml:S1:2845:3	O
number	TRULICITY.xml:S1:2849:6	O
of	TRULICITY.xml:S1:2856:2	O
patients	TRULICITY.xml:S1:2859:8	O
that	TRULICITY.xml:S1:2868:4	O
reported	TRULICITY.xml:S1:2873:8	O
at	TRULICITY.xml:S1:2882:2	O
least	TRULICITY.xml:S1:2885:5	O
1	TRULICITY.xml:S1:2891:1	O
treatment	TRULICITY.xml:S1:2893:9	O
-	TRULICITY.xml:S1:2902:1	O
emergent	TRULICITY.xml:S1:2904:8	O
occurrence	TRULICITY.xml:S1:2913:10	O
of	TRULICITY.xml:S1:2924:2	O
the	TRULICITY.xml:S1:2927:3	O
adverse	TRULICITY.xml:S1:2931:7	O
reaction	TRULICITY.xml:S1:2939:8	O
.	TRULICITY.xml:S1:2947:1	O

Adverse	TRULICITY.xml:S1:2959:7	O

Reaction	TRULICITY.xml:S1:2967:8	O
Placebo	TRULICITY.xml:S1:2986:7	O
(	TRULICITY.xml:S1:2997:1	O
N	TRULICITY.xml:S1:2998:1	O
568	TRULICITY.xml:S1:3000:3	O
)	TRULICITY.xml:S1:3003:1	O
Trulicity	TRULICITY.xml:S1:3015:9	O
0.75	TRULICITY.xml:S1:3025:4	O
mg	TRULICITY.xml:S1:3030:2	O
(	TRULICITY.xml:S1:3036:1	O
N	TRULICITY.xml:S1:3037:1	O
836	TRULICITY.xml:S1:3039:3	O
)	TRULICITY.xml:S1:3042:1	O
Trulicity	TRULICITY.xml:S1:3054:9	O
1.5	TRULICITY.xml:S1:3064:3	O
mg	TRULICITY.xml:S1:3068:2	O
(	TRULICITY.xml:S1:3074:1	O
N	TRULICITY.xml:S1:3075:1	O
834	TRULICITY.xml:S1:3077:3	O
)	TRULICITY.xml:S1:3080:1	O

Nausea	TRULICITY.xml:S1:3093:6	B-AdverseReaction
5.3	TRULICITY.xml:S1:3120:3	O
12.4	TRULICITY.xml:S1:3147:4	O
21.1	TRULICITY.xml:S1:3172:4	O

Diarrhea	TRULICITY.xml:S1:3202:8	B-AdverseReaction
a	TRULICITY.xml:S1:3212:1	O
6.7	TRULICITY.xml:S1:3229:3	O
8.9	TRULICITY.xml:S1:3256:3	O
12.6	TRULICITY.xml:S1:3281:4	O

Vomiting	TRULICITY.xml:S1:3311:8	B-AdverseReaction
b	TRULICITY.xml:S1:3321:1	O
2.3	TRULICITY.xml:S1:3338:3	O
6.0	TRULICITY.xml:S1:3365:3	O
12.7	TRULICITY.xml:S1:3390:4	O

Abdominal	TRULICITY.xml:S1:3420:9	B-AdverseReaction
Pain	TRULICITY.xml:S1:3430:4	I-AdverseReaction
c	TRULICITY.xml:S1:3436:1	O
4.9	TRULICITY.xml:S1:3447:3	O
6.5	TRULICITY.xml:S1:3474:3	O
9.4	TRULICITY.xml:S1:3499:3	O

Decreased	TRULICITY.xml:S1:3529:9	B-AdverseReaction
Appetite	TRULICITY.xml:S1:3539:8	I-AdverseReaction
1.6	TRULICITY.xml:S1:3556:3	O
4.9	TRULICITY.xml:S1:3583:3	O
8.6	TRULICITY.xml:S1:3608:3	O

Dyspepsia	TRULICITY.xml:S1:3638:9	B-AdverseReaction
2.3	TRULICITY.xml:S1:3665:3	O
4.1	TRULICITY.xml:S1:3692:3	O
5.8	TRULICITY.xml:S1:3717:3	O

Fatigue	TRULICITY.xml:S1:3747:7	B-AdverseReaction
d	TRULICITY.xml:S1:3756:1	O
2.6	TRULICITY.xml:S1:3774:3	O
4.2	TRULICITY.xml:S1:3801:3	O
5.6	TRULICITY.xml:S1:3826:3	O

Gastrointestinal	TRULICITY.xml:S1:3869:16	O
Adverse	TRULICITY.xml:S1:3886:7	O
Reactions	TRULICITY.xml:S1:3894:9	O

In	TRULICITY.xml:S1:3910:2	O

the	TRULICITY.xml:S1:3913:3	O
pool	TRULICITY.xml:S1:3917:4	O
of	TRULICITY.xml:S1:3922:2	O
placebo	TRULICITY.xml:S1:3925:7	O
-	TRULICITY.xml:S1:3932:1	O
controlled	TRULICITY.xml:S1:3933:10	O
trials	TRULICITY.xml:S1:3944:6	O
,	TRULICITY.xml:S1:3950:1	O
gastrointestinal	TRULICITY.xml:S1:3952:16	B-AdverseReaction
adverse	TRULICITY.xml:S1:3969:7	I-AdverseReaction
reactions	TRULICITY.xml:S1:3977:9	I-AdverseReaction
occurred	TRULICITY.xml:S1:3987:8	O
more	TRULICITY.xml:S1:3996:4	O
frequently	TRULICITY.xml:S1:4001:10	O
among	TRULICITY.xml:S1:4012:5	O
patients	TRULICITY.xml:S1:4018:8	O
receiving	TRULICITY.xml:S1:4027:9	O
TRULICITY	TRULICITY.xml:S1:4037:9	O
than	TRULICITY.xml:S1:4047:4	O
placebo	TRULICITY.xml:S1:4052:7	O
(	TRULICITY.xml:S1:4060:1	O
placebo	TRULICITY.xml:S1:4061:7	O
21.3%	TRULICITY.xml:S1:4069:5	O
,	TRULICITY.xml:S1:4074:1	O
0.75	TRULICITY.xml:S1:4076:4	O
mg	TRULICITY.xml:S1:4081:2	O
31.6%	TRULICITY.xml:S1:4084:5	O
,	TRULICITY.xml:S1:4089:1	O
1.5	TRULICITY.xml:S1:4091:3	O
mg	TRULICITY.xml:S1:4095:2	O
41.0%	TRULICITY.xml:S1:4098:5	O
)	TRULICITY.xml:S1:4103:1	O
.	TRULICITY.xml:S1:4104:1	O

More	TRULICITY.xml:S1:4106:4	O
patients	TRULICITY.xml:S1:4111:8	O
receiving	TRULICITY.xml:S1:4120:9	O
TRULICITY	TRULICITY.xml:S1:4130:9	O
0.75	TRULICITY.xml:S1:4140:4	O
mg	TRULICITY.xml:S1:4145:2	O
(	TRULICITY.xml:S1:4148:1	O
1.3%	TRULICITY.xml:S1:4149:4	O
)	TRULICITY.xml:S1:4153:1	O
and	TRULICITY.xml:S1:4155:3	O
TRULICITY	TRULICITY.xml:S1:4159:9	O
1.5	TRULICITY.xml:S1:4169:3	O
mg	TRULICITY.xml:S1:4173:2	O
(	TRULICITY.xml:S1:4176:1	O
3.5%	TRULICITY.xml:S1:4177:4	O
)	TRULICITY.xml:S1:4181:1	O
discontinued	TRULICITY.xml:S1:4183:12	O
treatment	TRULICITY.xml:S1:4196:9	O
due	TRULICITY.xml:S1:4206:3	O
to	TRULICITY.xml:S1:4210:2	O
gastrointestinal	TRULICITY.xml:S1:4213:16	B-AdverseReaction
adverse	TRULICITY.xml:S1:4230:7	I-AdverseReaction
reactions	TRULICITY.xml:S1:4238:9	I-AdverseReaction
than	TRULICITY.xml:S1:4248:4	O
patients	TRULICITY.xml:S1:4253:8	O
receiving	TRULICITY.xml:S1:4262:9	O
placebo	TRULICITY.xml:S1:4272:7	O
(	TRULICITY.xml:S1:4280:1	O
0.2%	TRULICITY.xml:S1:4281:4	O
)	TRULICITY.xml:S1:4285:1	O
.	TRULICITY.xml:S1:4286:1	O

Investigators	TRULICITY.xml:S1:4288:13	O
graded	TRULICITY.xml:S1:4302:6	O
the	TRULICITY.xml:S1:4309:3	O
severity	TRULICITY.xml:S1:4313:8	O
of	TRULICITY.xml:S1:4322:2	O
gastrointestinal	TRULICITY.xml:S1:4325:16	B-AdverseReaction
adverse	TRULICITY.xml:S1:4342:7	I-AdverseReaction
reactions	TRULICITY.xml:S1:4350:9	I-AdverseReaction
occurring	TRULICITY.xml:S1:4360:9	O
on	TRULICITY.xml:S1:4370:2	O
0.75	TRULICITY.xml:S1:4373:4	O
mg	TRULICITY.xml:S1:4378:2	O
and	TRULICITY.xml:S1:4381:3	O
1.5	TRULICITY.xml:S1:4385:3	O
mg	TRULICITY.xml:S1:4389:2	O
of	TRULICITY.xml:S1:4392:2	O
TRULICITY	TRULICITY.xml:S1:4395:9	O
as	TRULICITY.xml:S1:4405:2	O
"	TRULICITY.xml:S1:4408:1	O
mild	TRULICITY.xml:S1:4409:4	B-Severity
"	TRULICITY.xml:S1:4413:1	O
in	TRULICITY.xml:S1:4415:2	O
58%	TRULICITY.xml:S1:4418:3	O
and	TRULICITY.xml:S1:4422:3	O
48%	TRULICITY.xml:S1:4426:3	O
of	TRULICITY.xml:S1:4430:2	O
cases	TRULICITY.xml:S1:4433:5	O
,	TRULICITY.xml:S1:4438:1	O
respectively	TRULICITY.xml:S1:4440:12	O
,	TRULICITY.xml:S1:4452:1	O
"	TRULICITY.xml:S1:4454:1	O
moderate	TRULICITY.xml:S1:4455:8	B-Severity
"	TRULICITY.xml:S1:4463:1	O
in	TRULICITY.xml:S1:4465:2	O
35%	TRULICITY.xml:S1:4468:3	O
and	TRULICITY.xml:S1:4472:3	O
42%	TRULICITY.xml:S1:4476:3	O
of	TRULICITY.xml:S1:4480:2	O
cases	TRULICITY.xml:S1:4483:5	O
,	TRULICITY.xml:S1:4488:1	O
respectively	TRULICITY.xml:S1:4490:12	O
,	TRULICITY.xml:S1:4502:1	O
or	TRULICITY.xml:S1:4504:2	O
"	TRULICITY.xml:S1:4507:1	O
severe	TRULICITY.xml:S1:4508:6	B-Severity
"	TRULICITY.xml:S1:4514:1	O
in	TRULICITY.xml:S1:4516:2	O
7%	TRULICITY.xml:S1:4519:2	O
and	TRULICITY.xml:S1:4522:3	O
11%	TRULICITY.xml:S1:4526:3	O
of	TRULICITY.xml:S1:4530:2	O
cases	TRULICITY.xml:S1:4533:5	O
,	TRULICITY.xml:S1:4538:1	O
respectively	TRULICITY.xml:S1:4540:12	O
.	TRULICITY.xml:S1:4552:1	O

In	TRULICITY.xml:S1:4558:2	O
addition	TRULICITY.xml:S1:4561:8	O
to	TRULICITY.xml:S1:4570:2	O
the	TRULICITY.xml:S1:4573:3	O
reactions	TRULICITY.xml:S1:4577:9	O
in	TRULICITY.xml:S1:4587:2	O
Table	TRULICITY.xml:S1:4591:5	O
1	TRULICITY.xml:S1:4597:1	O
,	TRULICITY.xml:S1:4600:1	O
the	TRULICITY.xml:S1:4602:3	O
following	TRULICITY.xml:S1:4606:9	O
adverse	TRULICITY.xml:S1:4616:7	O
reactions	TRULICITY.xml:S1:4624:9	O
were	TRULICITY.xml:S1:4634:4	O
reported	TRULICITY.xml:S1:4639:8	O
more	TRULICITY.xml:S1:4648:4	O
frequently	TRULICITY.xml:S1:4653:10	O
in	TRULICITY.xml:S1:4664:2	O
TRULICITY	TRULICITY.xml:S1:4667:9	O
-	TRULICITY.xml:S1:4676:1	O
treated	TRULICITY.xml:S1:4677:7	O
patients	TRULICITY.xml:S1:4685:8	O
than	TRULICITY.xml:S1:4694:4	O
placebo	TRULICITY.xml:S1:4699:7	O
(	TRULICITY.xml:S1:4707:1	O
frequencies	TRULICITY.xml:S1:4708:11	O
listed	TRULICITY.xml:S1:4720:6	O
,	TRULICITY.xml:S1:4726:1	O
respectively	TRULICITY.xml:S1:4728:12	O
,	TRULICITY.xml:S1:4740:1	O
as	TRULICITY.xml:S1:4742:2	O
:	TRULICITY.xml:S1:4744:1	O
placebo	TRULICITY.xml:S1:4746:7	O
;	TRULICITY.xml:S1:4753:1	O
0.75	TRULICITY.xml:S1:4755:4	O
mg	TRULICITY.xml:S1:4760:2	O
;	TRULICITY.xml:S1:4762:1	O
1.5	TRULICITY.xml:S1:4764:3	O
mg	TRULICITY.xml:S1:4768:2	O
)	TRULICITY.xml:S1:4770:1	O
:	TRULICITY.xml:S1:4771:1	O
constipation	TRULICITY.xml:S1:4773:12	B-AdverseReaction
(	TRULICITY.xml:S1:4786:1	O
0.7%	TRULICITY.xml:S1:4787:4	O
,	TRULICITY.xml:S1:4791:1	O
3.9%	TRULICITY.xml:S1:4793:4	O
,	TRULICITY.xml:S1:4797:1	O
3.7%	TRULICITY.xml:S1:4799:4	O
)	TRULICITY.xml:S1:4803:1	O
,	TRULICITY.xml:S1:4804:1	O
flatulence	TRULICITY.xml:S1:4806:10	B-AdverseReaction
(	TRULICITY.xml:S1:4817:1	O
1.4%	TRULICITY.xml:S1:4818:4	O
,	TRULICITY.xml:S1:4822:1	O
1.4%	TRULICITY.xml:S1:4824:4	O
,	TRULICITY.xml:S1:4828:1	O
3.4%	TRULICITY.xml:S1:4830:4	O
)	TRULICITY.xml:S1:4834:1	O
,	TRULICITY.xml:S1:4835:1	O
abdominal	TRULICITY.xml:S1:4837:9	B-AdverseReaction
distension	TRULICITY.xml:S1:4847:10	I-AdverseReaction
(	TRULICITY.xml:S1:4858:1	O
0.7%	TRULICITY.xml:S1:4859:4	O
,	TRULICITY.xml:S1:4863:1	O
2.9%	TRULICITY.xml:S1:4865:4	O
,	TRULICITY.xml:S1:4869:1	O
2.3%	TRULICITY.xml:S1:4871:4	O
)	TRULICITY.xml:S1:4875:1	O
,	TRULICITY.xml:S1:4876:1	O
gastroesophageal	TRULICITY.xml:S1:4878:16	B-AdverseReaction
reflux	TRULICITY.xml:S1:4895:6	I-AdverseReaction
disease	TRULICITY.xml:S1:4902:7	I-AdverseReaction
(	TRULICITY.xml:S1:4910:1	O
0.5%	TRULICITY.xml:S1:4911:4	O
,	TRULICITY.xml:S1:4915:1	O
1.7%	TRULICITY.xml:S1:4917:4	O
,	TRULICITY.xml:S1:4921:1	O
2.0%	TRULICITY.xml:S1:4923:4	O
)	TRULICITY.xml:S1:4927:1	O
,	TRULICITY.xml:S1:4928:1	O
and	TRULICITY.xml:S1:4930:3	O
eructation	TRULICITY.xml:S1:4934:10	B-AdverseReaction
(	TRULICITY.xml:S1:4945:1	O
0.2%	TRULICITY.xml:S1:4946:4	O
,	TRULICITY.xml:S1:4950:1	O
0.6%	TRULICITY.xml:S1:4952:4	O
,	TRULICITY.xml:S1:4956:1	O
1.6%	TRULICITY.xml:S1:4958:4	O
)	TRULICITY.xml:S1:4962:1	O
.	TRULICITY.xml:S1:4963:1	O

Pool	TRULICITY.xml:S1:4973:4	O
of	TRULICITY.xml:S1:4978:2	O
Placebo	TRULICITY.xml:S1:4981:7	O
-	TRULICITY.xml:S1:4988:1	O
and	TRULICITY.xml:S1:4990:3	O
Active	TRULICITY.xml:S1:4994:6	O
-	TRULICITY.xml:S1:5000:1	O
Controlled	TRULICITY.xml:S1:5001:10	O
Trials	TRULICITY.xml:S1:5012:6	O

The	TRULICITY.xml:S1:5025:3	O
occurrence	TRULICITY.xml:S1:5029:10	O
of	TRULICITY.xml:S1:5040:2	O
adverse	TRULICITY.xml:S1:5043:7	O
reactions	TRULICITY.xml:S1:5051:9	O
was	TRULICITY.xml:S1:5061:3	O
also	TRULICITY.xml:S1:5065:4	O
evaluated	TRULICITY.xml:S1:5070:9	O
in	TRULICITY.xml:S1:5080:2	O
a	TRULICITY.xml:S1:5083:1	O
larger	TRULICITY.xml:S1:5085:6	O
pool	TRULICITY.xml:S1:5092:4	O
of	TRULICITY.xml:S1:5097:2	O
patients	TRULICITY.xml:S1:5100:8	O
with	TRULICITY.xml:S1:5109:4	O
type	TRULICITY.xml:S1:5114:4	O
2	TRULICITY.xml:S1:5119:1	O
diabetes	TRULICITY.xml:S1:5121:8	O
participating	TRULICITY.xml:S1:5130:13	O
in	TRULICITY.xml:S1:5144:2	O
6	TRULICITY.xml:S1:5147:1	O
placebo	TRULICITY.xml:S1:5149:7	O
-	TRULICITY.xml:S1:5156:1	O
and	TRULICITY.xml:S1:5158:3	O
active	TRULICITY.xml:S1:5162:6	O
-	TRULICITY.xml:S1:5168:1	O
controlled	TRULICITY.xml:S1:5169:10	O
trials	TRULICITY.xml:S1:5180:6	O
evaluating	TRULICITY.xml:S1:5187:10	O
the	TRULICITY.xml:S1:5198:3	O
use	TRULICITY.xml:S1:5202:3	O
of	TRULICITY.xml:S1:5206:2	O
TRULICITY	TRULICITY.xml:S1:5209:9	O
as	TRULICITY.xml:S1:5219:2	O
monotherapy	TRULICITY.xml:S1:5222:11	O
and	TRULICITY.xml:S1:5234:3	O
add	TRULICITY.xml:S1:5238:3	O
-	TRULICITY.xml:S1:5241:1	O
on	TRULICITY.xml:S1:5242:2	O
therapy	TRULICITY.xml:S1:5245:7	O
to	TRULICITY.xml:S1:5253:2	O
oral	TRULICITY.xml:S1:5256:4	O
medications	TRULICITY.xml:S1:5261:11	O
or	TRULICITY.xml:S1:5273:2	O
insulin	TRULICITY.xml:S1:5276:7	O
.	TRULICITY.xml:S1:5283:1	O

[	TRULICITY.xml:S1:5286:1	O
see	TRULICITY.xml:S1:5287:3	O
Clinical	TRULICITY.xml:S1:5291:8	O
Studies	TRULICITY.xml:S1:5300:7	O
(	TRULICITY.xml:S1:5308:1	O
14	TRULICITY.xml:S1:5311:2	O
)]	TRULICITY.xml:S1:5315:2	O
.	TRULICITY.xml:S1:5319:1	O

In	TRULICITY.xml:S1:5321:2	O
this	TRULICITY.xml:S1:5324:4	O
pool	TRULICITY.xml:S1:5329:4	O
,	TRULICITY.xml:S1:5333:1	O
a	TRULICITY.xml:S1:5335:1	O
total	TRULICITY.xml:S1:5337:5	O
of	TRULICITY.xml:S1:5343:2	O
3342	TRULICITY.xml:S1:5346:4	O
patients	TRULICITY.xml:S1:5351:8	O
with	TRULICITY.xml:S1:5360:4	O
type	TRULICITY.xml:S1:5365:4	O
2	TRULICITY.xml:S1:5370:1	O
diabetes	TRULICITY.xml:S1:5372:8	O
were	TRULICITY.xml:S1:5381:4	O
treated	TRULICITY.xml:S1:5386:7	O
with	TRULICITY.xml:S1:5394:4	O
TRULICITY	TRULICITY.xml:S1:5399:9	O
for	TRULICITY.xml:S1:5409:3	O
a	TRULICITY.xml:S1:5413:1	O
mean	TRULICITY.xml:S1:5415:4	O
duration	TRULICITY.xml:S1:5420:8	O
of	TRULICITY.xml:S1:5429:2	O
52	TRULICITY.xml:S1:5432:2	O
weeks	TRULICITY.xml:S1:5435:5	O
.	TRULICITY.xml:S1:5440:1	O

The	TRULICITY.xml:S1:5442:3	O
mean	TRULICITY.xml:S1:5446:4	O
age	TRULICITY.xml:S1:5451:3	O
of	TRULICITY.xml:S1:5455:2	O
patients	TRULICITY.xml:S1:5458:8	O
was	TRULICITY.xml:S1:5467:3	O
56	TRULICITY.xml:S1:5471:2	O
years	TRULICITY.xml:S1:5474:5	O
,	TRULICITY.xml:S1:5479:1	O
2%	TRULICITY.xml:S1:5481:2	O
were	TRULICITY.xml:S1:5484:4	O
75	TRULICITY.xml:S1:5489:2	O
years	TRULICITY.xml:S1:5492:5	O
or	TRULICITY.xml:S1:5498:2	O
older	TRULICITY.xml:S1:5501:5	O
and	TRULICITY.xml:S1:5507:3	O
51%	TRULICITY.xml:S1:5511:3	O
were	TRULICITY.xml:S1:5515:4	O
male	TRULICITY.xml:S1:5520:4	O
.	TRULICITY.xml:S1:5524:1	O

The	TRULICITY.xml:S1:5526:3	O
population	TRULICITY.xml:S1:5530:10	O
in	TRULICITY.xml:S1:5541:2	O
these	TRULICITY.xml:S1:5544:5	O
studies	TRULICITY.xml:S1:5550:7	O
was	TRULICITY.xml:S1:5558:3	O
71%	TRULICITY.xml:S1:5562:3	O
White	TRULICITY.xml:S1:5566:5	O
,	TRULICITY.xml:S1:5571:1	O
7%	TRULICITY.xml:S1:5573:2	O
Black	TRULICITY.xml:S1:5576:5	O
or	TRULICITY.xml:S1:5582:2	O
African	TRULICITY.xml:S1:5585:7	O
American	TRULICITY.xml:S1:5593:8	O
,	TRULICITY.xml:S1:5601:1	O
11%	TRULICITY.xml:S1:5603:3	O
Asian	TRULICITY.xml:S1:5607:5	O
;	TRULICITY.xml:S1:5612:1	O
32%	TRULICITY.xml:S1:5614:3	O
were	TRULICITY.xml:S1:5618:4	O
of	TRULICITY.xml:S1:5623:2	O
Hispanic	TRULICITY.xml:S1:5626:8	O
or	TRULICITY.xml:S1:5635:2	O
Latino	TRULICITY.xml:S1:5638:6	O
ethnicity	TRULICITY.xml:S1:5645:9	O
.	TRULICITY.xml:S1:5654:1	O

At	TRULICITY.xml:S1:5656:2	O
baseline	TRULICITY.xml:S1:5659:8	O
,	TRULICITY.xml:S1:5667:1	O
the	TRULICITY.xml:S1:5669:3	O
population	TRULICITY.xml:S1:5673:10	O
had	TRULICITY.xml:S1:5684:3	O
diabetes	TRULICITY.xml:S1:5688:8	O
for	TRULICITY.xml:S1:5697:3	O
an	TRULICITY.xml:S1:5701:2	O
average	TRULICITY.xml:S1:5704:7	O
of	TRULICITY.xml:S1:5712:2	O
8.2	TRULICITY.xml:S1:5715:3	O
years	TRULICITY.xml:S1:5719:5	O
and	TRULICITY.xml:S1:5725:3	O
had	TRULICITY.xml:S1:5729:3	O
a	TRULICITY.xml:S1:5733:1	O
mean	TRULICITY.xml:S1:5735:4	O
HbA1c	TRULICITY.xml:S1:5740:5	O
of	TRULICITY.xml:S1:5746:2	O
7.6	TRULICITY.xml:S1:5749:3	O
-	TRULICITY.xml:S1:5752:1	O
8.5%	TRULICITY.xml:S1:5753:4	O
.	TRULICITY.xml:S1:5757:1	O

At	TRULICITY.xml:S1:5759:2	O
baseline	TRULICITY.xml:S1:5762:8	O
,	TRULICITY.xml:S1:5770:1	O
5.2%	TRULICITY.xml:S1:5772:4	O
of	TRULICITY.xml:S1:5777:2	O
the	TRULICITY.xml:S1:5780:3	O
population	TRULICITY.xml:S1:5784:10	O
reported	TRULICITY.xml:S1:5795:8	O
retinopathy	TRULICITY.xml:S1:5804:11	O
.	TRULICITY.xml:S1:5815:1	O

Baseline	TRULICITY.xml:S1:5817:8	O
estimated	TRULICITY.xml:S1:5826:9	O
renal	TRULICITY.xml:S1:5836:5	O
function	TRULICITY.xml:S1:5842:8	O
was	TRULICITY.xml:S1:5851:3	O
normal	TRULICITY.xml:S1:5855:6	O
or	TRULICITY.xml:S1:5862:2	O
mildly	TRULICITY.xml:S1:5865:6	O
impaired	TRULICITY.xml:S1:5872:8	O
(	TRULICITY.xml:S1:5881:1	O
eGFR	TRULICITY.xml:S1:5882:4	O
60	TRULICITY.xml:S1:5889:2	O
ml	TRULICITY.xml:S1:5892:2	O
min	TRULICITY.xml:S1:5895:3	O
1.73	TRULICITY.xml:S1:5899:4	O
m2	TRULICITY.xml:S1:5904:2	O
)	TRULICITY.xml:S1:5906:1	O
in	TRULICITY.xml:S1:5908:2	O
95.7%	TRULICITY.xml:S1:5911:5	O
of	TRULICITY.xml:S1:5917:2	O
the	TRULICITY.xml:S1:5920:3	O
TRULICITY	TRULICITY.xml:S1:5924:9	O
population	TRULICITY.xml:S1:5934:10	O
.	TRULICITY.xml:S1:5944:1	O

In	TRULICITY.xml:S1:5950:2	O
the	TRULICITY.xml:S1:5953:3	O
pool	TRULICITY.xml:S1:5957:4	O
of	TRULICITY.xml:S1:5962:2	O
placebo	TRULICITY.xml:S1:5965:7	O
-	TRULICITY.xml:S1:5972:1	O
and	TRULICITY.xml:S1:5974:3	O
active	TRULICITY.xml:S1:5978:6	O
-	TRULICITY.xml:S1:5984:1	O
controlled	TRULICITY.xml:S1:5985:10	O
trials	TRULICITY.xml:S1:5996:6	O
,	TRULICITY.xml:S1:6002:1	O
the	TRULICITY.xml:S1:6004:3	O
types	TRULICITY.xml:S1:6008:5	O
and	TRULICITY.xml:S1:6014:3	O
frequency	TRULICITY.xml:S1:6018:9	O
of	TRULICITY.xml:S1:6028:2	O
common	TRULICITY.xml:S1:6031:6	O
adverse	TRULICITY.xml:S1:6038:7	O
reactions	TRULICITY.xml:S1:6046:9	O
,	TRULICITY.xml:S1:6055:1	O
excluding	TRULICITY.xml:S1:6057:9	O
hypoglycemia	TRULICITY.xml:S1:6067:12	B-AdverseReaction
,	TRULICITY.xml:S1:6079:1	O
were	TRULICITY.xml:S1:6081:4	O
similar	TRULICITY.xml:S1:6086:7	O
to	TRULICITY.xml:S1:6094:2	O
those	TRULICITY.xml:S1:6097:5	O
listed	TRULICITY.xml:S1:6103:6	O
in	TRULICITY.xml:S1:6110:2	O
Table	TRULICITY.xml:S1:6114:5	O
1	TRULICITY.xml:S1:6120:1	O
.	TRULICITY.xml:S1:6123:1	O

Other	TRULICITY.xml:S1:6133:5	O
Adverse	TRULICITY.xml:S1:6139:7	O
Reactions	TRULICITY.xml:S1:6147:9	O

Hypoglycemia	TRULICITY.xml:S1:6167:12	O

Table	TRULICITY.xml:S1:6188:5	O
2	TRULICITY.xml:S1:6194:1	O
summarizes	TRULICITY.xml:S1:6197:10	O
the	TRULICITY.xml:S1:6208:3	O
incidence	TRULICITY.xml:S1:6212:9	O
of	TRULICITY.xml:S1:6222:2	O
documented	TRULICITY.xml:S1:6225:10	O
symptomatic	TRULICITY.xml:S1:6236:11	B-AdverseReaction
(	TRULICITY.xml:S1:6248:1	O
70	TRULICITY.xml:S1:6251:2	O
mg	TRULICITY.xml:S1:6254:2	O
dL	TRULICITY.xml:S1:6257:2	O
glucose	TRULICITY.xml:S1:6260:7	O
threshold	TRULICITY.xml:S1:6268:9	O
)	TRULICITY.xml:S1:6277:1	O
and	TRULICITY.xml:S1:6279:3	O
severe	TRULICITY.xml:S1:6283:6	B-Severity
hypoglycemia	TRULICITY.xml:S1:6290:12	I-AdverseReaction
in	TRULICITY.xml:S1:6303:2	O
the	TRULICITY.xml:S1:6306:3	O
placebo	TRULICITY.xml:S1:6310:7	O
-	TRULICITY.xml:S1:6317:1	O
controlled	TRULICITY.xml:S1:6318:10	O
clinical	TRULICITY.xml:S1:6329:8	O
studies	TRULICITY.xml:S1:6338:7	O
.	TRULICITY.xml:S1:6345:1	O

Table	TRULICITY.xml:S1:6351:5	O
2	TRULICITY.xml:S1:6357:1	O
:	TRULICITY.xml:S1:6358:1	O
Incidence	TRULICITY.xml:S1:6360:9	O
(	TRULICITY.xml:S1:6370:1	O
)	TRULICITY.xml:S1:6372:1	O
of	TRULICITY.xml:S1:6374:2	O
Documented	TRULICITY.xml:S1:6377:10	O
Symptomatic	TRULICITY.xml:S1:6388:11	B-AdverseReaction
and	TRULICITY.xml:S1:6400:3	O
Severe	TRULICITY.xml:S1:6404:6	B-Severity
Hypoglycemia	TRULICITY.xml:S1:6411:12	I-AdverseReaction
Adverse	TRULICITY.xml:S1:6424:7	O
Reactions	TRULICITY.xml:S1:6432:9	O
in	TRULICITY.xml:S1:6442:2	O
Placebo	TRULICITY.xml:S1:6445:7	O
-	TRULICITY.xml:S1:6452:1	O
Controlled	TRULICITY.xml:S1:6453:10	O
Trials	TRULICITY.xml:S1:6464:6	O

Placebo	TRULICITY.xml:S1:6502:7	O
TRULICITY	TRULICITY.xml:S1:6529:9	O
0.75	TRULICITY.xml:S1:6539:4	O
mg	TRULICITY.xml:S1:6544:2	O
TRULICITY	TRULICITY.xml:S1:6556:9	O
1.5	TRULICITY.xml:S1:6566:3	O
mg	TRULICITY.xml:S1:6570:2	O

Add	TRULICITY.xml:S1:6586:3	O
-	TRULICITY.xml:S1:6589:1	O
on	TRULICITY.xml:S1:6590:2	O
to	TRULICITY.xml:S1:6593:2	O
Metformin	TRULICITY.xml:S1:6596:9	O

(	TRULICITY.xml:S1:6621:1	O
26	TRULICITY.xml:S1:6622:2	O
weeks	TRULICITY.xml:S1:6625:5	O
)	TRULICITY.xml:S1:6630:1	O
N	TRULICITY.xml:S1:6643:1	O
177	TRULICITY.xml:S1:6645:3	O
N	TRULICITY.xml:S1:6670:1	O
302	TRULICITY.xml:S1:6672:3	O
N	TRULICITY.xml:S1:6697:1	O
304	TRULICITY.xml:S1:6699:3	O

Documented	TRULICITY.xml:S1:6731:10	O
symptomatic	TRULICITY.xml:S1:6742:11	O
1.1%	TRULICITY.xml:S1:6755:4	O
2.6%	TRULICITY.xml:S1:6782:4	O
5.6%	TRULICITY.xml:S1:6809:4	O

Severe	TRULICITY.xml:S1:6845:6	O
0	TRULICITY.xml:S1:6866:1	O
0	TRULICITY.xml:S1:6893:1	O
0	TRULICITY.xml:S1:6920:1	O

Add	TRULICITY.xml:S1:6952:3	O
-	TRULICITY.xml:S1:6955:1	O
on	TRULICITY.xml:S1:6956:2	O
to	TRULICITY.xml:S1:6959:2	O
Metformin	TRULICITY.xml:S1:6962:9	O
Pioglitazone	TRULICITY.xml:S1:6974:12	O

(	TRULICITY.xml:S1:7000:1	O
26	TRULICITY.xml:S1:7001:2	O
weeks	TRULICITY.xml:S1:7004:5	O
)	TRULICITY.xml:S1:7009:1	O
N	TRULICITY.xml:S1:7022:1	O
141	TRULICITY.xml:S1:7024:3	O
N	TRULICITY.xml:S1:7049:1	O
280	TRULICITY.xml:S1:7051:3	O
N	TRULICITY.xml:S1:7076:1	O
279	TRULICITY.xml:S1:7078:3	O

Documented	TRULICITY.xml:S1:7110:10	O
symptomatic	TRULICITY.xml:S1:7121:11	O
1.4%	TRULICITY.xml:S1:7134:4	O
4.6%	TRULICITY.xml:S1:7161:4	O
5.0%	TRULICITY.xml:S1:7188:4	O

Severe	TRULICITY.xml:S1:7224:6	O
0	TRULICITY.xml:S1:7245:1	O
0	TRULICITY.xml:S1:7272:1	O
0	TRULICITY.xml:S1:7299:1	O

Hypoglycemia	TRULICITY.xml:S1:7338:12	B-AdverseReaction
was	TRULICITY.xml:S1:7351:3	O
more	TRULICITY.xml:S1:7355:4	O
frequent	TRULICITY.xml:S1:7360:8	O
when	TRULICITY.xml:S1:7369:4	O
TRULICITY	TRULICITY.xml:S1:7374:9	O
was	TRULICITY.xml:S1:7384:3	O
used	TRULICITY.xml:S1:7388:4	O
in	TRULICITY.xml:S1:7393:2	O
combination	TRULICITY.xml:S1:7396:11	O
with	TRULICITY.xml:S1:7408:4	O
a	TRULICITY.xml:S1:7413:1	O
sulfonylurea	TRULICITY.xml:S1:7415:12	O
or	TRULICITY.xml:S1:7428:2	O
insulin	TRULICITY.xml:S1:7431:7	O
[	TRULICITY.xml:S1:7440:1	O
see	TRULICITY.xml:S1:7441:3	O
Warnings	TRULICITY.xml:S1:7445:8	O
and	TRULICITY.xml:S1:7454:3	O
Precautions	TRULICITY.xml:S1:7458:11	O
(	TRULICITY.xml:S1:7470:1	O
5.3	TRULICITY.xml:S1:7473:3	O
)]	TRULICITY.xml:S1:7478:2	O
.	TRULICITY.xml:S1:7482:1	O

Documented	TRULICITY.xml:S1:7484:10	O
symptomatic	TRULICITY.xml:S1:7495:11	B-AdverseReaction
hypoglycemia	TRULICITY.xml:S1:7507:12	I-AdverseReaction
occurred	TRULICITY.xml:S1:7520:8	O
in	TRULICITY.xml:S1:7529:2	O
39%	TRULICITY.xml:S1:7532:3	O
and	TRULICITY.xml:S1:7536:3	O
40%	TRULICITY.xml:S1:7540:3	O
of	TRULICITY.xml:S1:7544:2	O
patients	TRULICITY.xml:S1:7547:8	O
when	TRULICITY.xml:S1:7556:4	O
TRULICITY	TRULICITY.xml:S1:7561:9	O
0.75	TRULICITY.xml:S1:7571:4	O
mg	TRULICITY.xml:S1:7576:2	O
and	TRULICITY.xml:S1:7579:3	O
1.5	TRULICITY.xml:S1:7583:3	O
mg	TRULICITY.xml:S1:7587:2	O
,	TRULICITY.xml:S1:7589:1	O
respectively	TRULICITY.xml:S1:7591:12	O
,	TRULICITY.xml:S1:7603:1	O
was	TRULICITY.xml:S1:7605:3	O
co	TRULICITY.xml:S1:7609:2	O
-	TRULICITY.xml:S1:7611:1	O
administered	TRULICITY.xml:S1:7612:12	O
with	TRULICITY.xml:S1:7625:4	O
a	TRULICITY.xml:S1:7630:1	O
sulfonylurea	TRULICITY.xml:S1:7632:12	O
.	TRULICITY.xml:S1:7644:1	O

Severe	TRULICITY.xml:S1:7646:6	B-Severity
hypoglycemia	TRULICITY.xml:S1:7653:12	B-AdverseReaction
occurred	TRULICITY.xml:S1:7666:8	O
in	TRULICITY.xml:S1:7675:2	O
0%	TRULICITY.xml:S1:7678:2	O
and	TRULICITY.xml:S1:7681:3	O
0.7%	TRULICITY.xml:S1:7685:4	O
of	TRULICITY.xml:S1:7690:2	O
patients	TRULICITY.xml:S1:7693:8	O
when	TRULICITY.xml:S1:7702:4	O
TRULICITY	TRULICITY.xml:S1:7707:9	O
0.75	TRULICITY.xml:S1:7717:4	O
mg	TRULICITY.xml:S1:7722:2	O
and	TRULICITY.xml:S1:7725:3	O
1.5	TRULICITY.xml:S1:7729:3	O
mg	TRULICITY.xml:S1:7733:2	O
,	TRULICITY.xml:S1:7735:1	O
respectively	TRULICITY.xml:S1:7737:12	O
,	TRULICITY.xml:S1:7749:1	O
was	TRULICITY.xml:S1:7751:3	O
co	TRULICITY.xml:S1:7755:2	O
-	TRULICITY.xml:S1:7757:1	O
administered	TRULICITY.xml:S1:7758:12	O
with	TRULICITY.xml:S1:7771:4	O
a	TRULICITY.xml:S1:7776:1	O
sulfonylurea	TRULICITY.xml:S1:7778:12	O
.	TRULICITY.xml:S1:7790:1	O

Documented	TRULICITY.xml:S1:7792:10	O
symptomatic	TRULICITY.xml:S1:7803:11	B-AdverseReaction
hypoglycemia	TRULICITY.xml:S1:7815:12	I-AdverseReaction
occurred	TRULICITY.xml:S1:7828:8	O
in	TRULICITY.xml:S1:7837:2	O
85%	TRULICITY.xml:S1:7840:3	O
and	TRULICITY.xml:S1:7844:3	O
80%	TRULICITY.xml:S1:7848:3	O
of	TRULICITY.xml:S1:7852:2	O
patients	TRULICITY.xml:S1:7855:8	O
when	TRULICITY.xml:S1:7864:4	O
TRULICITY	TRULICITY.xml:S1:7869:9	O
0.75	TRULICITY.xml:S1:7879:4	O
mg	TRULICITY.xml:S1:7884:2	O
and	TRULICITY.xml:S1:7887:3	O
1.5	TRULICITY.xml:S1:7891:3	O
mg	TRULICITY.xml:S1:7895:2	O
,	TRULICITY.xml:S1:7897:1	O
respectively	TRULICITY.xml:S1:7899:12	O
,	TRULICITY.xml:S1:7911:1	O
was	TRULICITY.xml:S1:7913:3	O
co	TRULICITY.xml:S1:7917:2	O
-	TRULICITY.xml:S1:7919:1	O
administered	TRULICITY.xml:S1:7920:12	O
with	TRULICITY.xml:S1:7933:4	O
prandial	TRULICITY.xml:S1:7938:8	O
insulin	TRULICITY.xml:S1:7947:7	O
.	TRULICITY.xml:S1:7954:1	O

Severe	TRULICITY.xml:S1:7956:6	B-Severity
hypoglycemia	TRULICITY.xml:S1:7963:12	B-AdverseReaction
occurred	TRULICITY.xml:S1:7976:8	O
in	TRULICITY.xml:S1:7985:2	O
2.4%	TRULICITY.xml:S1:7988:4	O
and	TRULICITY.xml:S1:7993:3	O
3.4%	TRULICITY.xml:S1:7997:4	O
of	TRULICITY.xml:S1:8002:2	O
patients	TRULICITY.xml:S1:8005:8	O
when	TRULICITY.xml:S1:8014:4	O
TRULICITY	TRULICITY.xml:S1:8019:9	O
0.75	TRULICITY.xml:S1:8029:4	O
mg	TRULICITY.xml:S1:8034:2	O
and	TRULICITY.xml:S1:8037:3	O
1.5	TRULICITY.xml:S1:8041:3	O
mg	TRULICITY.xml:S1:8045:2	O
,	TRULICITY.xml:S1:8047:1	O
respectively	TRULICITY.xml:S1:8049:12	O
,	TRULICITY.xml:S1:8061:1	O
was	TRULICITY.xml:S1:8063:3	O
co	TRULICITY.xml:S1:8067:2	O
-	TRULICITY.xml:S1:8069:1	O
administered	TRULICITY.xml:S1:8070:12	O
with	TRULICITY.xml:S1:8083:4	O
prandial	TRULICITY.xml:S1:8088:8	O
insulin	TRULICITY.xml:S1:8097:7	O
.	TRULICITY.xml:S1:8104:1	O

Heart	TRULICITY.xml:S1:8114:5	O

Rate	TRULICITY.xml:S1:8120:4	O
Increase	TRULICITY.xml:S1:8125:8	O
and	TRULICITY.xml:S1:8134:3	O
Tachycardia	TRULICITY.xml:S1:8138:11	O
Related	TRULICITY.xml:S1:8150:7	O
Adverse	TRULICITY.xml:S1:8158:7	O
Reactions	TRULICITY.xml:S1:8166:9	O
.	TRULICITY.xml:S1:8175:1	O

TRULICITY	TRULICITY.xml:S1:8183:9	O
0.75	TRULICITY.xml:S1:8193:4	O
mg	TRULICITY.xml:S1:8198:2	O
and	TRULICITY.xml:S1:8201:3	O
1.5	TRULICITY.xml:S1:8205:3	O
mg	TRULICITY.xml:S1:8209:2	O
resulted	TRULICITY.xml:S1:8212:8	O
in	TRULICITY.xml:S1:8221:2	O
a	TRULICITY.xml:S1:8224:1	O
mean	TRULICITY.xml:S1:8226:4	O
increase	TRULICITY.xml:S1:8231:8	B-AdverseReaction
in	TRULICITY.xml:S1:8240:2	I-AdverseReaction
heart	TRULICITY.xml:S1:8243:5	I-AdverseReaction
rate	TRULICITY.xml:S1:8249:4	I-AdverseReaction
(	TRULICITY.xml:S1:8254:1	O
HR	TRULICITY.xml:S1:8255:2	I-AdverseReaction
)	TRULICITY.xml:S1:8257:1	O
of	TRULICITY.xml:S1:8259:2	O
2	TRULICITY.xml:S1:8262:1	O
-	TRULICITY.xml:S1:8263:1	O
4	TRULICITY.xml:S1:8264:1	O
beats	TRULICITY.xml:S1:8266:5	O
per	TRULICITY.xml:S1:8272:3	O
minute	TRULICITY.xml:S1:8276:6	O
(	TRULICITY.xml:S1:8283:1	O
bpm	TRULICITY.xml:S1:8284:3	O
)	TRULICITY.xml:S1:8287:1	O
.	TRULICITY.xml:S1:8288:1	O

The	TRULICITY.xml:S1:8290:3	O
long	TRULICITY.xml:S1:8294:4	O
-	TRULICITY.xml:S1:8298:1	O
term	TRULICITY.xml:S1:8299:4	O
clinical	TRULICITY.xml:S1:8304:8	O
effects	TRULICITY.xml:S1:8313:7	O
of	TRULICITY.xml:S1:8321:2	O
the	TRULICITY.xml:S1:8324:3	O
increase	TRULICITY.xml:S1:8328:8	B-AdverseReaction
in	TRULICITY.xml:S1:8337:2	I-AdverseReaction
HR	TRULICITY.xml:S1:8340:2	I-AdverseReaction
have	TRULICITY.xml:S1:8343:4	O
not	TRULICITY.xml:S1:8348:3	O
been	TRULICITY.xml:S1:8352:4	O
established	TRULICITY.xml:S1:8357:11	O
[	TRULICITY.xml:S1:8370:1	O
see	TRULICITY.xml:S1:8371:3	O
Warnings	TRULICITY.xml:S1:8375:8	O
and	TRULICITY.xml:S1:8384:3	O
Precautions	TRULICITY.xml:S1:8388:11	O
(	TRULICITY.xml:S1:8400:1	O
5.7	TRULICITY.xml:S1:8403:3	O
)]	TRULICITY.xml:S1:8408:2	O
.	TRULICITY.xml:S1:8412:1	O

Adverse	TRULICITY.xml:S1:8418:7	O
reactions	TRULICITY.xml:S1:8426:9	O
of	TRULICITY.xml:S1:8436:2	O
sinus	TRULICITY.xml:S1:8439:5	B-AdverseReaction
tachycardia	TRULICITY.xml:S1:8445:11	I-AdverseReaction
were	TRULICITY.xml:S1:8457:4	O
reported	TRULICITY.xml:S1:8462:8	O
more	TRULICITY.xml:S1:8471:4	O
frequently	TRULICITY.xml:S1:8476:10	O
in	TRULICITY.xml:S1:8487:2	O
patients	TRULICITY.xml:S1:8490:8	O
exposed	TRULICITY.xml:S1:8499:7	O
to	TRULICITY.xml:S1:8507:2	O
TRULICITY	TRULICITY.xml:S1:8510:9	O
.	TRULICITY.xml:S1:8519:1	O

Sinus	TRULICITY.xml:S1:8521:5	B-AdverseReaction
tachycardia	TRULICITY.xml:S1:8527:11	I-AdverseReaction
was	TRULICITY.xml:S1:8539:3	O
reported	TRULICITY.xml:S1:8543:8	O
in	TRULICITY.xml:S1:8552:2	O
3.0%	TRULICITY.xml:S1:8555:4	O
,	TRULICITY.xml:S1:8559:1	O
2.8%	TRULICITY.xml:S1:8561:4	O
,	TRULICITY.xml:S1:8565:1	O
and	TRULICITY.xml:S1:8567:3	O
5.6%	TRULICITY.xml:S1:8571:4	O
of	TRULICITY.xml:S1:8576:2	O
patient	TRULICITY.xml:S1:8579:7	O
treated	TRULICITY.xml:S1:8587:7	O
with	TRULICITY.xml:S1:8595:4	O
placebo	TRULICITY.xml:S1:8600:7	O
,	TRULICITY.xml:S1:8607:1	O
TRULICITY	TRULICITY.xml:S1:8609:9	O
0.75	TRULICITY.xml:S1:8619:4	O
mg	TRULICITY.xml:S1:8624:2	O
and	TRULICITY.xml:S1:8627:3	O
TRULICITY	TRULICITY.xml:S1:8631:9	O
1.5	TRULICITY.xml:S1:8641:3	O
mg	TRULICITY.xml:S1:8645:2	O
,	TRULICITY.xml:S1:8647:1	O
respectively	TRULICITY.xml:S1:8649:12	O
.	TRULICITY.xml:S1:8661:1	O

Persistence	TRULICITY.xml:S1:8663:11	B-AdverseReaction
of	TRULICITY.xml:S1:8675:2	I-AdverseReaction
sinus	TRULICITY.xml:S1:8678:5	I-AdverseReaction
tachycardia	TRULICITY.xml:S1:8684:11	I-AdverseReaction
(	TRULICITY.xml:S1:8696:1	O
reported	TRULICITY.xml:S1:8697:8	O
at	TRULICITY.xml:S1:8706:2	O
more	TRULICITY.xml:S1:8709:4	O
than	TRULICITY.xml:S1:8714:4	O
2	TRULICITY.xml:S1:8719:1	O
visits	TRULICITY.xml:S1:8721:6	O
)	TRULICITY.xml:S1:8727:1	O
was	TRULICITY.xml:S1:8729:3	O
reported	TRULICITY.xml:S1:8733:8	O
in	TRULICITY.xml:S1:8742:2	O
0.2%	TRULICITY.xml:S1:8745:4	O
,	TRULICITY.xml:S1:8749:1	O
0.4%	TRULICITY.xml:S1:8751:4	O
and	TRULICITY.xml:S1:8756:3	O
1.6%	TRULICITY.xml:S1:8760:4	O
of	TRULICITY.xml:S1:8765:2	O
patients	TRULICITY.xml:S1:8768:8	O
treated	TRULICITY.xml:S1:8777:7	O
with	TRULICITY.xml:S1:8785:4	O
placebo	TRULICITY.xml:S1:8790:7	O
,	TRULICITY.xml:S1:8797:1	O
TRULICITY	TRULICITY.xml:S1:8799:9	O
0.75	TRULICITY.xml:S1:8809:4	O
mg	TRULICITY.xml:S1:8814:2	O
and	TRULICITY.xml:S1:8817:3	O
TRULICITY	TRULICITY.xml:S1:8821:9	O
1.5	TRULICITY.xml:S1:8831:3	O
mg	TRULICITY.xml:S1:8835:2	O
,	TRULICITY.xml:S1:8837:1	O
respectively	TRULICITY.xml:S1:8839:12	O
.	TRULICITY.xml:S1:8851:1	O

Episodes	TRULICITY.xml:S1:8853:8	O
of	TRULICITY.xml:S1:8862:2	O
sinus	TRULICITY.xml:S1:8865:5	B-AdverseReaction
tachycardia	TRULICITY.xml:S1:8871:11	I-AdverseReaction
,	TRULICITY.xml:S1:8882:1	O
associated	TRULICITY.xml:S1:8884:10	O
with	TRULICITY.xml:S1:8895:4	O
a	TRULICITY.xml:S1:8900:1	O
concomitant	TRULICITY.xml:S1:8902:11	O
increase	TRULICITY.xml:S1:8914:8	B-AdverseReaction
from	TRULICITY.xml:S1:8923:4	O
baseline	TRULICITY.xml:S1:8928:8	O
in	TRULICITY.xml:S1:8937:2	I-AdverseReaction
heart	TRULICITY.xml:S1:8940:5	I-AdverseReaction
rate	TRULICITY.xml:S1:8946:4	I-AdverseReaction
of	TRULICITY.xml:S1:8951:2	O
15	TRULICITY.xml:S1:8956:2	O
beats	TRULICITY.xml:S1:8959:5	O
per	TRULICITY.xml:S1:8965:3	O
minute	TRULICITY.xml:S1:8969:6	O
,	TRULICITY.xml:S1:8975:1	O
were	TRULICITY.xml:S1:8977:4	O
reported	TRULICITY.xml:S1:8982:8	O
in	TRULICITY.xml:S1:8991:2	O
0.7%	TRULICITY.xml:S1:8994:4	O
,	TRULICITY.xml:S1:8998:1	O
1.3%	TRULICITY.xml:S1:9000:4	O
and	TRULICITY.xml:S1:9005:3	O
2.2%	TRULICITY.xml:S1:9009:4	O
of	TRULICITY.xml:S1:9014:2	O
patient	TRULICITY.xml:S1:9017:7	O
treated	TRULICITY.xml:S1:9025:7	O
with	TRULICITY.xml:S1:9033:4	O
placebo	TRULICITY.xml:S1:9038:7	O
,	TRULICITY.xml:S1:9045:1	O
TRULICITY	TRULICITY.xml:S1:9047:9	O
0.75	TRULICITY.xml:S1:9057:4	O
mg	TRULICITY.xml:S1:9062:2	O
and	TRULICITY.xml:S1:9065:3	O
TRULICITY	TRULICITY.xml:S1:9069:9	O
1.5	TRULICITY.xml:S1:9079:3	O
mg	TRULICITY.xml:S1:9083:2	O
,	TRULICITY.xml:S1:9085:1	O
respectively	TRULICITY.xml:S1:9087:12	O
.	TRULICITY.xml:S1:9099:1	O

Immunogenicity	TRULICITY.xml:S1:9109:14	O

Across	TRULICITY.xml:S1:9130:6	O
four	TRULICITY.xml:S1:9137:4	O
Phase	TRULICITY.xml:S1:9142:5	O
2	TRULICITY.xml:S1:9148:1	O
and	TRULICITY.xml:S1:9150:3	O
five	TRULICITY.xml:S1:9154:4	O
Phase	TRULICITY.xml:S1:9159:5	O
3	TRULICITY.xml:S1:9165:1	O
clinical	TRULICITY.xml:S1:9167:8	O
studies	TRULICITY.xml:S1:9176:7	O
,	TRULICITY.xml:S1:9183:1	O
64	TRULICITY.xml:S1:9185:2	O
(	TRULICITY.xml:S1:9188:1	O
1.6%	TRULICITY.xml:S1:9189:4	O
)	TRULICITY.xml:S1:9193:1	O
TRULICITY	TRULICITY.xml:S1:9195:9	O
treated	TRULICITY.xml:S1:9205:7	O
patients	TRULICITY.xml:S1:9213:8	O
developed	TRULICITY.xml:S1:9222:9	O
anti	TRULICITY.xml:S1:9232:4	O
-	TRULICITY.xml:S1:9236:1	O
drug	TRULICITY.xml:S1:9237:4	O
antibodies	TRULICITY.xml:S1:9242:10	O
(	TRULICITY.xml:S1:9253:1	O
ADAs	TRULICITY.xml:S1:9254:4	O
)	TRULICITY.xml:S1:9258:1	O
to	TRULICITY.xml:S1:9260:2	O
the	TRULICITY.xml:S1:9263:3	O
active	TRULICITY.xml:S1:9267:6	O
ingredient	TRULICITY.xml:S1:9274:10	O
in	TRULICITY.xml:S1:9285:2	O
TRULICITY	TRULICITY.xml:S1:9288:9	O
(	TRULICITY.xml:S1:9298:1	O
i	TRULICITY.xml:S1:9299:1	O
.	TRULICITY.xml:S1:9300:1	O
e	TRULICITY.xml:S1:9301:1	O
.	TRULICITY.xml:S1:9302:1	O
,	TRULICITY.xml:S1:9303:1	O
dulaglutide	TRULICITY.xml:S1:9305:11	O
)	TRULICITY.xml:S1:9316:1	O
.	TRULICITY.xml:S1:9317:1	O

Of	TRULICITY.xml:S1:9323:2	O
the	TRULICITY.xml:S1:9326:3	O
64	TRULICITY.xml:S1:9330:2	O
dulaglutide	TRULICITY.xml:S1:9333:11	O
-	TRULICITY.xml:S1:9344:1	O
treated	TRULICITY.xml:S1:9345:7	O
patients	TRULICITY.xml:S1:9353:8	O
that	TRULICITY.xml:S1:9362:4	O
developed	TRULICITY.xml:S1:9367:9	O
dulaglutide	TRULICITY.xml:S1:9377:11	O
ADAs	TRULICITY.xml:S1:9389:4	O
,	TRULICITY.xml:S1:9393:1	O
34	TRULICITY.xml:S1:9395:2	O
patients	TRULICITY.xml:S1:9398:8	O
(	TRULICITY.xml:S1:9407:1	O
0.9%	TRULICITY.xml:S1:9408:4	O
of	TRULICITY.xml:S1:9413:2	O
the	TRULICITY.xml:S1:9416:3	O
overall	TRULICITY.xml:S1:9420:7	O
population	TRULICITY.xml:S1:9428:10	O
)	TRULICITY.xml:S1:9438:1	O
had	TRULICITY.xml:S1:9440:3	O
dulaglutide	TRULICITY.xml:S1:9444:11	O
-	TRULICITY.xml:S1:9455:1	O
neutralizing	TRULICITY.xml:S1:9456:12	O
antibodies	TRULICITY.xml:S1:9469:10	O
,	TRULICITY.xml:S1:9479:1	O
and	TRULICITY.xml:S1:9481:3	O
36	TRULICITY.xml:S1:9485:2	O
patients	TRULICITY.xml:S1:9488:8	O
(	TRULICITY.xml:S1:9497:1	O
0.9%	TRULICITY.xml:S1:9498:4	O
of	TRULICITY.xml:S1:9503:2	O
the	TRULICITY.xml:S1:9506:3	O
overall	TRULICITY.xml:S1:9510:7	O
population	TRULICITY.xml:S1:9518:10	O
)	TRULICITY.xml:S1:9528:1	O
developed	TRULICITY.xml:S1:9530:9	O
antibodies	TRULICITY.xml:S1:9540:10	O
against	TRULICITY.xml:S1:9551:7	O
native	TRULICITY.xml:S1:9559:6	O
GLP	TRULICITY.xml:S1:9566:3	O
-	TRULICITY.xml:S1:9569:1	O
1	TRULICITY.xml:S1:9570:1	O
.	TRULICITY.xml:S1:9571:1	O

The	TRULICITY.xml:S1:9577:3	O
detection	TRULICITY.xml:S1:9581:9	O
of	TRULICITY.xml:S1:9591:2	O
antibody	TRULICITY.xml:S1:9594:8	O
formation	TRULICITY.xml:S1:9603:9	O
is	TRULICITY.xml:S1:9613:2	O
highly	TRULICITY.xml:S1:9616:6	O
dependent	TRULICITY.xml:S1:9623:9	O
on	TRULICITY.xml:S1:9633:2	O
the	TRULICITY.xml:S1:9636:3	O
sensitivity	TRULICITY.xml:S1:9640:11	O
and	TRULICITY.xml:S1:9652:3	O
specificity	TRULICITY.xml:S1:9656:11	O
of	TRULICITY.xml:S1:9668:2	O
the	TRULICITY.xml:S1:9671:3	O
assay	TRULICITY.xml:S1:9675:5	O
.	TRULICITY.xml:S1:9680:1	O

Additionally	TRULICITY.xml:S1:9682:12	O
,	TRULICITY.xml:S1:9694:1	O
the	TRULICITY.xml:S1:9696:3	O
observed	TRULICITY.xml:S1:9700:8	O
incidence	TRULICITY.xml:S1:9709:9	O
of	TRULICITY.xml:S1:9719:2	O
antibody	TRULICITY.xml:S1:9722:8	O
(	TRULICITY.xml:S1:9731:1	O
including	TRULICITY.xml:S1:9732:9	O
neutralizing	TRULICITY.xml:S1:9742:12	O
antibody	TRULICITY.xml:S1:9755:8	O
)	TRULICITY.xml:S1:9763:1	O
positivity	TRULICITY.xml:S1:9765:10	O
in	TRULICITY.xml:S1:9776:2	O
an	TRULICITY.xml:S1:9779:2	O
assay	TRULICITY.xml:S1:9782:5	O
may	TRULICITY.xml:S1:9788:3	O
be	TRULICITY.xml:S1:9792:2	O
influenced	TRULICITY.xml:S1:9795:10	O
by	TRULICITY.xml:S1:9806:2	O
several	TRULICITY.xml:S1:9809:7	O
factors	TRULICITY.xml:S1:9817:7	O
including	TRULICITY.xml:S1:9825:9	O
assay	TRULICITY.xml:S1:9835:5	O
methodology	TRULICITY.xml:S1:9841:11	O
,	TRULICITY.xml:S1:9852:1	O
sample	TRULICITY.xml:S1:9854:6	O
handling	TRULICITY.xml:S1:9861:8	O
,	TRULICITY.xml:S1:9869:1	O
timing	TRULICITY.xml:S1:9871:6	O
of	TRULICITY.xml:S1:9878:2	O
sample	TRULICITY.xml:S1:9881:6	O
collection	TRULICITY.xml:S1:9888:10	O
,	TRULICITY.xml:S1:9898:1	O
concomitant	TRULICITY.xml:S1:9900:11	O
medications	TRULICITY.xml:S1:9912:11	O
,	TRULICITY.xml:S1:9923:1	O
and	TRULICITY.xml:S1:9925:3	O
underlying	TRULICITY.xml:S1:9929:10	O
disease	TRULICITY.xml:S1:9940:7	O
.	TRULICITY.xml:S1:9947:1	O

For	TRULICITY.xml:S1:9949:3	O
these	TRULICITY.xml:S1:9953:5	O
reasons	TRULICITY.xml:S1:9959:7	O
,	TRULICITY.xml:S1:9966:1	O
the	TRULICITY.xml:S1:9968:3	O
incidence	TRULICITY.xml:S1:9972:9	O
of	TRULICITY.xml:S1:9982:2	O
antibodies	TRULICITY.xml:S1:9985:10	O
to	TRULICITY.xml:S1:9996:2	O
dulaglutide	TRULICITY.xml:S1:9999:11	O
cannot	TRULICITY.xml:S1:10011:6	O
be	TRULICITY.xml:S1:10018:2	O
directly	TRULICITY.xml:S1:10021:8	O
compared	TRULICITY.xml:S1:10030:8	O
with	TRULICITY.xml:S1:10039:4	O
the	TRULICITY.xml:S1:10044:3	O
incidence	TRULICITY.xml:S1:10048:9	O
of	TRULICITY.xml:S1:10058:2	O
antibodies	TRULICITY.xml:S1:10061:10	O
of	TRULICITY.xml:S1:10072:2	O
other	TRULICITY.xml:S1:10075:5	O
products	TRULICITY.xml:S1:10081:8	O
.	TRULICITY.xml:S1:10089:1	O

Hypersensitivity	TRULICITY.xml:S1:10099:16	O

Systemic	TRULICITY.xml:S1:10122:8	B-AdverseReaction
hypersensitivity	TRULICITY.xml:S1:10131:16	I-AdverseReaction
adverse	TRULICITY.xml:S1:10148:7	O
reactions	TRULICITY.xml:S1:10156:9	O
sometimes	TRULICITY.xml:S1:10166:9	O
severe	TRULICITY.xml:S1:10176:6	B-Severity
(	TRULICITY.xml:S1:10183:1	O
e	TRULICITY.xml:S1:10184:1	O
.	TRULICITY.xml:S1:10185:1	O
g	TRULICITY.xml:S1:10186:1	O
.	TRULICITY.xml:S1:10187:1	O
,	TRULICITY.xml:S1:10188:1	O
severe	TRULICITY.xml:S1:10190:6	B-Severity
urticaria	TRULICITY.xml:S1:10197:9	B-AdverseReaction
,	TRULICITY.xml:S1:10206:1	O
systemic	TRULICITY.xml:S1:10208:8	B-AdverseReaction
rash	TRULICITY.xml:S1:10217:4	I-AdverseReaction
,	TRULICITY.xml:S1:10221:1	O
facial	TRULICITY.xml:S1:10223:6	B-AdverseReaction
edema	TRULICITY.xml:S1:10230:5	I-AdverseReaction
,	TRULICITY.xml:S1:10235:1	O
lip	TRULICITY.xml:S1:10237:3	B-AdverseReaction
swelling	TRULICITY.xml:S1:10241:8	I-AdverseReaction
)	TRULICITY.xml:S1:10249:1	O
occurred	TRULICITY.xml:S1:10251:8	O
in	TRULICITY.xml:S1:10260:2	O
0.5%	TRULICITY.xml:S1:10263:4	O
of	TRULICITY.xml:S1:10268:2	O
patients	TRULICITY.xml:S1:10271:8	O
on	TRULICITY.xml:S1:10280:2	O
TRULICITY	TRULICITY.xml:S1:10283:9	O
in	TRULICITY.xml:S1:10293:2	O
the	TRULICITY.xml:S1:10296:3	O
four	TRULICITY.xml:S1:10300:4	O
Phase	TRULICITY.xml:S1:10305:5	O
2	TRULICITY.xml:S1:10311:1	O
and	TRULICITY.xml:S1:10313:3	O
five	TRULICITY.xml:S1:10317:4	O
Phase	TRULICITY.xml:S1:10322:5	O
3	TRULICITY.xml:S1:10328:1	O
studies	TRULICITY.xml:S1:10330:7	O
.	TRULICITY.xml:S1:10337:1	O

Injection	TRULICITY.xml:S1:10347:9	O
-	TRULICITY.xml:S1:10356:1	O
site	TRULICITY.xml:S1:10357:4	O
Reactions	TRULICITY.xml:S1:10362:9	O

In	TRULICITY.xml:S1:10378:2	O
the	TRULICITY.xml:S1:10381:3	O
placebo	TRULICITY.xml:S1:10385:7	O
-	TRULICITY.xml:S1:10392:1	O
controlled	TRULICITY.xml:S1:10393:10	O
studies	TRULICITY.xml:S1:10404:7	O
,	TRULICITY.xml:S1:10411:1	O
injection	TRULICITY.xml:S1:10413:9	B-AdverseReaction
-	TRULICITY.xml:S1:10422:1	I-AdverseReaction
site	TRULICITY.xml:S1:10423:4	I-AdverseReaction
reactions	TRULICITY.xml:S1:10428:9	I-AdverseReaction
(	TRULICITY.xml:S1:10438:1	O
e	TRULICITY.xml:S1:10439:1	O
.	TRULICITY.xml:S1:10440:1	O
g	TRULICITY.xml:S1:10441:1	O
.	TRULICITY.xml:S1:10442:1	O
,	TRULICITY.xml:S1:10443:1	O
injection	TRULICITY.xml:S1:10445:9	B-AdverseReaction
-	TRULICITY.xml:S1:10454:1	I-AdverseReaction
site	TRULICITY.xml:S1:10455:4	I-AdverseReaction
rash	TRULICITY.xml:S1:10460:4	I-AdverseReaction
,	TRULICITY.xml:S1:10464:1	O
erythema	TRULICITY.xml:S1:10466:8	I-AdverseReaction
)	TRULICITY.xml:S1:10474:1	O
were	TRULICITY.xml:S1:10476:4	O
reported	TRULICITY.xml:S1:10481:8	O
in	TRULICITY.xml:S1:10490:2	O
0.5%	TRULICITY.xml:S1:10493:4	O
of	TRULICITY.xml:S1:10498:2	O
TRULICITY	TRULICITY.xml:S1:10501:9	O
-	TRULICITY.xml:S1:10510:1	O
treated	TRULICITY.xml:S1:10511:7	O
patients	TRULICITY.xml:S1:10519:8	O
and	TRULICITY.xml:S1:10528:3	O
in	TRULICITY.xml:S1:10532:2	O
0.0%	TRULICITY.xml:S1:10535:4	O
of	TRULICITY.xml:S1:10540:2	O
placebo	TRULICITY.xml:S1:10543:7	O
-	TRULICITY.xml:S1:10550:1	O
treated	TRULICITY.xml:S1:10551:7	O
patients	TRULICITY.xml:S1:10559:8	O
.	TRULICITY.xml:S1:10567:1	O

PR	TRULICITY.xml:S1:10577:2	O
Interval	TRULICITY.xml:S1:10580:8	O
Prolongation	TRULICITY.xml:S1:10589:12	O
and	TRULICITY.xml:S1:10602:3	O
Adverse	TRULICITY.xml:S1:10606:7	O
Reactions	TRULICITY.xml:S1:10614:9	O
of	TRULICITY.xml:S1:10624:2	O
First	TRULICITY.xml:S1:10627:5	O
Degree	TRULICITY.xml:S1:10633:6	O
Atrioventricular	TRULICITY.xml:S1:10640:16	O
(	TRULICITY.xml:S1:10657:1	O
AV	TRULICITY.xml:S1:10658:2	O
)	TRULICITY.xml:S1:10660:1	O
Block	TRULICITY.xml:S1:10662:5	O

A	TRULICITY.xml:S1:10674:1	O
mean	TRULICITY.xml:S1:10676:4	O
increase	TRULICITY.xml:S1:10681:8	B-AdverseReaction
from	TRULICITY.xml:S1:10690:4	O
baseline	TRULICITY.xml:S1:10695:8	O
in	TRULICITY.xml:S1:10704:2	O
PR	TRULICITY.xml:S1:10707:2	I-AdverseReaction
interval	TRULICITY.xml:S1:10710:8	I-AdverseReaction
of	TRULICITY.xml:S1:10719:2	O
2	TRULICITY.xml:S1:10722:1	O
-	TRULICITY.xml:S1:10723:1	O
3	TRULICITY.xml:S1:10724:1	O
milliseconds	TRULICITY.xml:S1:10726:12	O
was	TRULICITY.xml:S1:10739:3	O
observed	TRULICITY.xml:S1:10743:8	O
in	TRULICITY.xml:S1:10752:2	O
TRULICITY	TRULICITY.xml:S1:10755:9	O
-	TRULICITY.xml:S1:10764:1	O
treated	TRULICITY.xml:S1:10765:7	O
patients	TRULICITY.xml:S1:10773:8	O
in	TRULICITY.xml:S1:10782:2	O
contrast	TRULICITY.xml:S1:10785:8	O
to	TRULICITY.xml:S1:10794:2	O
a	TRULICITY.xml:S1:10797:1	O
mean	TRULICITY.xml:S1:10799:4	O
decrease	TRULICITY.xml:S1:10804:8	O
of	TRULICITY.xml:S1:10813:2	O
0.9	TRULICITY.xml:S1:10816:3	O
millisecond	TRULICITY.xml:S1:10820:11	O
in	TRULICITY.xml:S1:10832:2	O
placebo	TRULICITY.xml:S1:10835:7	O
-	TRULICITY.xml:S1:10842:1	O
treated	TRULICITY.xml:S1:10843:7	O
patients	TRULICITY.xml:S1:10851:8	O
.	TRULICITY.xml:S1:10859:1	O

The	TRULICITY.xml:S1:10861:3	O
adverse	TRULICITY.xml:S1:10865:7	O
reaction	TRULICITY.xml:S1:10873:8	O
of	TRULICITY.xml:S1:10882:2	O
first	TRULICITY.xml:S1:10885:5	B-AdverseReaction
degree	TRULICITY.xml:S1:10891:6	I-AdverseReaction
AV	TRULICITY.xml:S1:10898:2	I-AdverseReaction
block	TRULICITY.xml:S1:10901:5	I-AdverseReaction
occurred	TRULICITY.xml:S1:10907:8	O
more	TRULICITY.xml:S1:10916:4	O
frequently	TRULICITY.xml:S1:10921:10	O
in	TRULICITY.xml:S1:10932:2	O
patients	TRULICITY.xml:S1:10935:8	O
treated	TRULICITY.xml:S1:10944:7	O
with	TRULICITY.xml:S1:10952:4	O
TRULICITY	TRULICITY.xml:S1:10957:9	O
than	TRULICITY.xml:S1:10967:4	O
placebo	TRULICITY.xml:S1:10972:7	O
(	TRULICITY.xml:S1:10980:1	O
0.9%	TRULICITY.xml:S1:10981:4	O
,	TRULICITY.xml:S1:10985:1	O
1.7%	TRULICITY.xml:S1:10987:4	O
and	TRULICITY.xml:S1:10992:3	O
2.3%	TRULICITY.xml:S1:10996:4	O
for	TRULICITY.xml:S1:11001:3	O
placebo	TRULICITY.xml:S1:11005:7	O
,	TRULICITY.xml:S1:11012:1	O
TRULICITY	TRULICITY.xml:S1:11014:9	O
0.75	TRULICITY.xml:S1:11024:4	O
mg	TRULICITY.xml:S1:11029:2	O
and	TRULICITY.xml:S1:11032:3	O
TRULICITY	TRULICITY.xml:S1:11036:9	O
1.5	TRULICITY.xml:S1:11046:3	O
mg	TRULICITY.xml:S1:11050:2	O
,	TRULICITY.xml:S1:11052:1	O
respectively	TRULICITY.xml:S1:11054:12	O
)	TRULICITY.xml:S1:11066:1	O
.	TRULICITY.xml:S1:11067:1	O

On	TRULICITY.xml:S1:11069:2	O
electrocardiograms	TRULICITY.xml:S1:11072:18	O
,	TRULICITY.xml:S1:11090:1	O
a	TRULICITY.xml:S1:11092:1	O
PR	TRULICITY.xml:S1:11094:2	B-AdverseReaction
interval	TRULICITY.xml:S1:11097:8	I-AdverseReaction
increase	TRULICITY.xml:S1:11106:8	I-AdverseReaction
to	TRULICITY.xml:S1:11115:2	O
at	TRULICITY.xml:S1:11118:2	O
least	TRULICITY.xml:S1:11121:5	O
220	TRULICITY.xml:S1:11127:3	O
milliseconds	TRULICITY.xml:S1:11131:12	O
was	TRULICITY.xml:S1:11144:3	O
observed	TRULICITY.xml:S1:11148:8	O
in	TRULICITY.xml:S1:11157:2	O
0.7%	TRULICITY.xml:S1:11160:4	O
,	TRULICITY.xml:S1:11164:1	O
2.5%	TRULICITY.xml:S1:11166:4	O
and	TRULICITY.xml:S1:11171:3	O
3.2%	TRULICITY.xml:S1:11175:4	O
of	TRULICITY.xml:S1:11180:2	O
patients	TRULICITY.xml:S1:11183:8	O
treated	TRULICITY.xml:S1:11192:7	O
with	TRULICITY.xml:S1:11200:4	O
placebo	TRULICITY.xml:S1:11205:7	O
,	TRULICITY.xml:S1:11212:1	O
TRULICITY	TRULICITY.xml:S1:11214:9	O
0.75	TRULICITY.xml:S1:11224:4	O
mg	TRULICITY.xml:S1:11229:2	O
and	TRULICITY.xml:S1:11232:3	O
TRULICITY	TRULICITY.xml:S1:11236:9	O
1.5	TRULICITY.xml:S1:11246:3	O
mg	TRULICITY.xml:S1:11250:2	O
,	TRULICITY.xml:S1:11252:1	O
respectively	TRULICITY.xml:S1:11254:12	O
.	TRULICITY.xml:S1:11266:1	O

Amylase	TRULICITY.xml:S1:11276:7	O
and	TRULICITY.xml:S1:11284:3	O
Lipase	TRULICITY.xml:S1:11288:6	O
Increase	TRULICITY.xml:S1:11295:8	O

Patients	TRULICITY.xml:S1:11310:8	O
exposed	TRULICITY.xml:S1:11319:7	O
to	TRULICITY.xml:S1:11327:2	O
TRULICITY	TRULICITY.xml:S1:11330:9	O
had	TRULICITY.xml:S1:11340:3	O
mean	TRULICITY.xml:S1:11344:4	O
increases	TRULICITY.xml:S1:11349:9	B-AdverseReaction
from	TRULICITY.xml:S1:11359:4	O
baseline	TRULICITY.xml:S1:11364:8	O
in	TRULICITY.xml:S1:11373:2	I-AdverseReaction
lipase	TRULICITY.xml:S1:11376:6	I-AdverseReaction
and	TRULICITY.xml:S1:11383:3	O
or	TRULICITY.xml:S1:11387:2	O
pancreatic	TRULICITY.xml:S1:11390:10	I-AdverseReaction
amylase	TRULICITY.xml:S1:11401:7	I-AdverseReaction
of	TRULICITY.xml:S1:11409:2	O
14%	TRULICITY.xml:S1:11412:3	O
to	TRULICITY.xml:S1:11416:2	O
20%	TRULICITY.xml:S1:11419:3	O
,	TRULICITY.xml:S1:11422:1	O
while	TRULICITY.xml:S1:11424:5	O
placebo	TRULICITY.xml:S1:11430:7	O
-	TRULICITY.xml:S1:11437:1	O
treated	TRULICITY.xml:S1:11438:7	O
patients	TRULICITY.xml:S1:11446:8	O
had	TRULICITY.xml:S1:11455:3	O
mean	TRULICITY.xml:S1:11459:4	O
increases	TRULICITY.xml:S1:11464:9	O
of	TRULICITY.xml:S1:11474:2	O
up	TRULICITY.xml:S1:11477:2	O
to	TRULICITY.xml:S1:11480:2	O
3%	TRULICITY.xml:S1:11483:2	O
.	TRULICITY.xml:S1:11485:1	O
\n\n	TRULICITY.xml:S2:0:2	O
BOXED	TRULICITY.xml:S2:6:5	O
WARNING	TRULICITY.xml:S2:12:7	O
:	TRULICITY.xml:S2:19:1	O
WARNING	TRULICITY.xml:S2:21:7	O
:	TRULICITY.xml:S2:28:1	O
RISK	TRULICITY.xml:S2:30:4	B-Factor
OF	TRULICITY.xml:S2:35:2	O
THYROID	TRULICITY.xml:S2:38:7	B-AdverseReaction
C	TRULICITY.xml:S2:46:1	I-AdverseReaction
-	TRULICITY.xml:S2:47:1	I-AdverseReaction
CELL	TRULICITY.xml:S2:48:4	I-AdverseReaction
TUMORS	TRULICITY.xml:S2:53:6	I-AdverseReaction
\n\n\n\n	TRULICITY.xml:S2:59:4	O
WARNING	TRULICITY.xml:S2:65:7	O
:	TRULICITY.xml:S2:72:1	O
RISK	TRULICITY.xml:S2:74:4	B-Factor
OF	TRULICITY.xml:S2:79:2	O
THYROID	TRULICITY.xml:S2:82:7	B-AdverseReaction
C	TRULICITY.xml:S2:90:1	I-AdverseReaction
-	TRULICITY.xml:S2:91:1	I-AdverseReaction
CELL	TRULICITY.xml:S2:92:4	I-AdverseReaction
TUMORS	TRULICITY.xml:S2:97:6	I-AdverseReaction
\n\n\n\n	TRULICITY.xml:S2:103:4	O
In	TRULICITY.xml:S2:114:2	O
male	TRULICITY.xml:S2:117:4	O
and	TRULICITY.xml:S2:122:3	O
female	TRULICITY.xml:S2:126:6	O
rats	TRULICITY.xml:S2:133:4	B-Animal
,	TRULICITY.xml:S2:137:1	O
dulaglutide	TRULICITY.xml:S2:139:11	O
causes	TRULICITY.xml:S2:151:6	O
a	TRULICITY.xml:S2:158:1	O
dose	TRULICITY.xml:S2:160:4	O
-	TRULICITY.xml:S2:164:1	O
related	TRULICITY.xml:S2:165:7	O
and	TRULICITY.xml:S2:173:3	O
treatment	TRULICITY.xml:S2:177:9	O
-	TRULICITY.xml:S2:186:1	O
duration	TRULICITY.xml:S2:187:8	O
-	TRULICITY.xml:S2:195:1	O
dependent	TRULICITY.xml:S2:196:9	O
increase	TRULICITY.xml:S2:206:8	O
in	TRULICITY.xml:S2:215:2	O
the	TRULICITY.xml:S2:218:3	O
incidence	TRULICITY.xml:S2:222:9	O
of	TRULICITY.xml:S2:232:2	O
thyroid	TRULICITY.xml:S2:235:7	B-AdverseReaction
C	TRULICITY.xml:S2:243:1	I-AdverseReaction
-	TRULICITY.xml:S2:244:1	I-AdverseReaction
cell	TRULICITY.xml:S2:245:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:250:6	I-AdverseReaction
(	TRULICITY.xml:S2:257:1	O
adenomas	TRULICITY.xml:S2:258:8	I-AdverseReaction
and	TRULICITY.xml:S2:267:3	O
carcinomas	TRULICITY.xml:S2:271:10	I-AdverseReaction
)	TRULICITY.xml:S2:281:1	O
after	TRULICITY.xml:S2:283:5	O
lifetime	TRULICITY.xml:S2:289:8	O
exposure	TRULICITY.xml:S2:298:8	O
.	TRULICITY.xml:S2:306:1	O

It	TRULICITY.xml:S2:308:2	O
is	TRULICITY.xml:S2:311:2	O
unknown	TRULICITY.xml:S2:314:7	B-Factor
whether	TRULICITY.xml:S2:322:7	O
TRULICITY	TRULICITY.xml:S2:330:9	O
causes	TRULICITY.xml:S2:340:6	O
thyroid	TRULICITY.xml:S2:347:7	B-AdverseReaction
C	TRULICITY.xml:S2:355:1	I-AdverseReaction
-	TRULICITY.xml:S2:356:1	I-AdverseReaction
cell	TRULICITY.xml:S2:357:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:362:6	I-AdverseReaction
,	TRULICITY.xml:S2:368:1	O
including	TRULICITY.xml:S2:370:9	O
medullary	TRULICITY.xml:S2:380:9	B-AdverseReaction
thyroid	TRULICITY.xml:S2:390:7	I-AdverseReaction
carcinoma	TRULICITY.xml:S2:398:9	I-AdverseReaction
(	TRULICITY.xml:S2:408:1	O
MTC	TRULICITY.xml:S2:409:3	B-AdverseReaction
)	TRULICITY.xml:S2:412:1	O
,	TRULICITY.xml:S2:413:1	O
in	TRULICITY.xml:S2:415:2	O
humans	TRULICITY.xml:S2:418:6	O
as	TRULICITY.xml:S2:425:2	O
human	TRULICITY.xml:S2:428:5	O
relevance	TRULICITY.xml:S2:434:9	O
of	TRULICITY.xml:S2:444:2	O
dulaglutide	TRULICITY.xml:S2:447:11	O
-	TRULICITY.xml:S2:458:1	O
induced	TRULICITY.xml:S2:459:7	O
rodent	TRULICITY.xml:S2:467:6	B-Animal
thyroid	TRULICITY.xml:S2:474:7	B-AdverseReaction
C	TRULICITY.xml:S2:482:1	I-AdverseReaction
-	TRULICITY.xml:S2:483:1	I-AdverseReaction
cell	TRULICITY.xml:S2:484:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:489:6	I-AdverseReaction
has	TRULICITY.xml:S2:496:3	O
not	TRULICITY.xml:S2:500:3	O
been	TRULICITY.xml:S2:504:4	O
determined	TRULICITY.xml:S2:509:10	O
[	TRULICITY.xml:S2:520:1	O
see	TRULICITY.xml:S2:521:3	O
Warnings	TRULICITY.xml:S2:525:8	O
and	TRULICITY.xml:S2:534:3	O
Precautions	TRULICITY.xml:S2:538:11	O
(	TRULICITY.xml:S2:550:1	O
5.1	TRULICITY.xml:S2:551:3	O
)	TRULICITY.xml:S2:554:1	O
,	TRULICITY.xml:S2:555:1	O
and	TRULICITY.xml:S2:557:3	O
Nonclinical	TRULICITY.xml:S2:561:11	O
Toxicology	TRULICITY.xml:S2:573:10	O
(	TRULICITY.xml:S2:584:1	O
13.1	TRULICITY.xml:S2:585:4	O
)]	TRULICITY.xml:S2:589:2	O
.	TRULICITY.xml:S2:591:1	O

TRULICITY	TRULICITY.xml:S2:598:9	O
is	TRULICITY.xml:S2:608:2	O
contraindicated	TRULICITY.xml:S2:611:15	O
in	TRULICITY.xml:S2:627:2	O
patients	TRULICITY.xml:S2:630:8	O
with	TRULICITY.xml:S2:639:4	O
a	TRULICITY.xml:S2:644:1	O
personal	TRULICITY.xml:S2:646:8	O
or	TRULICITY.xml:S2:655:2	O
family	TRULICITY.xml:S2:658:6	O
history	TRULICITY.xml:S2:665:7	O
of	TRULICITY.xml:S2:673:2	O
MTC	TRULICITY.xml:S2:676:3	O
and	TRULICITY.xml:S2:680:3	O
in	TRULICITY.xml:S2:684:2	O
patients	TRULICITY.xml:S2:687:8	O
with	TRULICITY.xml:S2:696:4	O
Multiple	TRULICITY.xml:S2:701:8	O
Endocrine	TRULICITY.xml:S2:710:9	O
Neoplasia	TRULICITY.xml:S2:720:9	O
syndrome	TRULICITY.xml:S2:730:8	O
type	TRULICITY.xml:S2:739:4	O
2	TRULICITY.xml:S2:744:1	O
(	TRULICITY.xml:S2:746:1	O
MEN	TRULICITY.xml:S2:747:3	O
2	TRULICITY.xml:S2:751:1	O
)	TRULICITY.xml:S2:752:1	O
.	TRULICITY.xml:S2:753:1	O

Counsel	TRULICITY.xml:S2:755:7	O
patients	TRULICITY.xml:S2:763:8	O
regarding	TRULICITY.xml:S2:772:9	O
the	TRULICITY.xml:S2:782:3	O
potential	TRULICITY.xml:S2:786:9	O
risk	TRULICITY.xml:S2:796:4	O
of	TRULICITY.xml:S2:801:2	O
MTC	TRULICITY.xml:S2:804:3	O
with	TRULICITY.xml:S2:808:4	O
use	TRULICITY.xml:S2:813:3	O
of	TRULICITY.xml:S2:817:2	O
TRULICITY	TRULICITY.xml:S2:820:9	O
and	TRULICITY.xml:S2:830:3	O
inform	TRULICITY.xml:S2:834:6	O
them	TRULICITY.xml:S2:841:4	O
of	TRULICITY.xml:S2:846:2	O
symptoms	TRULICITY.xml:S2:849:8	O
of	TRULICITY.xml:S2:858:2	O
thyroid	TRULICITY.xml:S2:861:7	O
tumors	TRULICITY.xml:S2:869:6	O
(	TRULICITY.xml:S2:876:1	O
e	TRULICITY.xml:S2:877:1	O
.	TRULICITY.xml:S2:878:1	O
g	TRULICITY.xml:S2:879:1	O
.	TRULICITY.xml:S2:880:1	O
,	TRULICITY.xml:S2:881:1	O
mass	TRULICITY.xml:S2:883:4	O
in	TRULICITY.xml:S2:888:2	O
the	TRULICITY.xml:S2:891:3	O
neck	TRULICITY.xml:S2:895:4	O
,	TRULICITY.xml:S2:899:1	O
dysphagia	TRULICITY.xml:S2:901:9	O
,	TRULICITY.xml:S2:910:1	O
dyspnea	TRULICITY.xml:S2:912:7	O
,	TRULICITY.xml:S2:919:1	O
persistent	TRULICITY.xml:S2:921:10	O
hoarseness	TRULICITY.xml:S2:932:10	O
)	TRULICITY.xml:S2:942:1	O
.	TRULICITY.xml:S2:943:1	O

Routine	TRULICITY.xml:S2:945:7	O
monitoring	TRULICITY.xml:S2:953:10	O
of	TRULICITY.xml:S2:964:2	O
serum	TRULICITY.xml:S2:967:5	O
calcitonin	TRULICITY.xml:S2:973:10	O
or	TRULICITY.xml:S2:984:2	O
using	TRULICITY.xml:S2:987:5	O
thyroid	TRULICITY.xml:S2:993:7	O
ultrasound	TRULICITY.xml:S2:1001:10	O
is	TRULICITY.xml:S2:1012:2	O
of	TRULICITY.xml:S2:1015:2	O
uncertain	TRULICITY.xml:S2:1018:9	O
value	TRULICITY.xml:S2:1028:5	O
for	TRULICITY.xml:S2:1034:3	O
early	TRULICITY.xml:S2:1038:5	O
detection	TRULICITY.xml:S2:1044:9	O
of	TRULICITY.xml:S2:1054:2	O
MTC	TRULICITY.xml:S2:1057:3	O
in	TRULICITY.xml:S2:1061:2	O
patients	TRULICITY.xml:S2:1064:8	O
treated	TRULICITY.xml:S2:1073:7	O
with	TRULICITY.xml:S2:1081:4	O
TRULICITY	TRULICITY.xml:S2:1086:9	O
[	TRULICITY.xml:S2:1096:1	O
see	TRULICITY.xml:S2:1097:3	O
Contraindications	TRULICITY.xml:S2:1101:17	O
(	TRULICITY.xml:S2:1119:1	O
4.1	TRULICITY.xml:S2:1120:3	O
)	TRULICITY.xml:S2:1123:1	O
and	TRULICITY.xml:S2:1125:3	O
Warnings	TRULICITY.xml:S2:1129:8	O
and	TRULICITY.xml:S2:1138:3	O
Precautions	TRULICITY.xml:S2:1142:11	O
(	TRULICITY.xml:S2:1154:1	O
5.1	TRULICITY.xml:S2:1155:3	O
)]	TRULICITY.xml:S2:1158:2	O
.	TRULICITY.xml:S2:1160:1	O

EXCERPT	TRULICITY.xml:S2:1169:7	O
:	TRULICITY.xml:S2:1176:1	O
WARNING	TRULICITY.xml:S2:1182:7	O
:	TRULICITY.xml:S2:1189:1	O
RISK	TRULICITY.xml:S2:1191:4	B-Factor
OF	TRULICITY.xml:S2:1196:2	O
THYROID	TRULICITY.xml:S2:1199:7	B-AdverseReaction
C	TRULICITY.xml:S2:1207:1	I-AdverseReaction
-	TRULICITY.xml:S2:1208:1	I-AdverseReaction
CELL	TRULICITY.xml:S2:1209:4	I-AdverseReaction
TUMORS	TRULICITY.xml:S2:1214:6	I-AdverseReaction
\n	TRULICITY.xml:S2:1222:1	O
\n\n	TRULICITY.xml:S2:1224:2	O
See	TRULICITY.xml:S2:1229:3	O
full	TRULICITY.xml:S2:1233:4	O
prescribing	TRULICITY.xml:S2:1238:11	O
information	TRULICITY.xml:S2:1250:11	O
for	TRULICITY.xml:S2:1262:3	O
complete	TRULICITY.xml:S2:1266:8	O
boxed	TRULICITY.xml:S2:1275:5	O
warning	TRULICITY.xml:S2:1281:7	O
.	TRULICITY.xml:S2:1288:1	O

Dulaglutide	TRULICITY.xml:S2:1299:11	O
causes	TRULICITY.xml:S2:1311:6	O
thyroid	TRULICITY.xml:S2:1318:7	B-AdverseReaction
C	TRULICITY.xml:S2:1326:1	I-AdverseReaction
-	TRULICITY.xml:S2:1327:1	I-AdverseReaction
cell	TRULICITY.xml:S2:1328:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:1333:6	I-AdverseReaction
in	TRULICITY.xml:S2:1340:2	O
rats	TRULICITY.xml:S2:1343:4	B-Animal
.	TRULICITY.xml:S2:1347:1	O

It	TRULICITY.xml:S2:1349:2	O
is	TRULICITY.xml:S2:1352:2	O
unknown	TRULICITY.xml:S2:1355:7	B-Factor
whether	TRULICITY.xml:S2:1363:7	O
TRULICITY	TRULICITY.xml:S2:1371:9	O
causes	TRULICITY.xml:S2:1381:6	O
thyroid	TRULICITY.xml:S2:1388:7	B-AdverseReaction
C	TRULICITY.xml:S2:1396:1	I-AdverseReaction
-	TRULICITY.xml:S2:1397:1	I-AdverseReaction
cell	TRULICITY.xml:S2:1398:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:1403:6	I-AdverseReaction
,	TRULICITY.xml:S2:1409:1	O
including	TRULICITY.xml:S2:1411:9	O
medullary	TRULICITY.xml:S2:1421:9	B-AdverseReaction
thyroid	TRULICITY.xml:S2:1431:7	I-AdverseReaction
carcinoma	TRULICITY.xml:S2:1439:9	I-AdverseReaction
(	TRULICITY.xml:S2:1449:1	O
MTC	TRULICITY.xml:S2:1450:3	B-AdverseReaction
)	TRULICITY.xml:S2:1453:1	O
,	TRULICITY.xml:S2:1454:1	O
in	TRULICITY.xml:S2:1456:2	O
humans	TRULICITY.xml:S2:1459:6	O
as	TRULICITY.xml:S2:1466:2	O
the	TRULICITY.xml:S2:1469:3	O
human	TRULICITY.xml:S2:1473:5	O
relevance	TRULICITY.xml:S2:1479:9	O
of	TRULICITY.xml:S2:1489:2	O
dulaglutide	TRULICITY.xml:S2:1492:11	O
-	TRULICITY.xml:S2:1503:1	O
induced	TRULICITY.xml:S2:1504:7	O
rodent	TRULICITY.xml:S2:1512:6	B-Animal
thyroid	TRULICITY.xml:S2:1519:7	B-AdverseReaction
C	TRULICITY.xml:S2:1527:1	I-AdverseReaction
-	TRULICITY.xml:S2:1528:1	I-AdverseReaction
cell	TRULICITY.xml:S2:1529:4	I-AdverseReaction
tumors	TRULICITY.xml:S2:1534:6	I-AdverseReaction
has	TRULICITY.xml:S2:1541:3	O
not	TRULICITY.xml:S2:1545:3	O
been	TRULICITY.xml:S2:1549:4	O
determined	TRULICITY.xml:S2:1554:10	O
(	TRULICITY.xml:S2:1565:1	O
5.1	TRULICITY.xml:S2:1566:3	O
,	TRULICITY.xml:S2:1569:1	O
13.1	TRULICITY.xml:S2:1571:4	O
)	TRULICITY.xml:S2:1575:1	O
.	TRULICITY.xml:S2:1576:1	O

TRULICITY	TRULICITY.xml:S2:1583:9	O
is	TRULICITY.xml:S2:1593:2	O
contraindicated	TRULICITY.xml:S2:1596:15	O
in	TRULICITY.xml:S2:1612:2	O
patients	TRULICITY.xml:S2:1615:8	O
with	TRULICITY.xml:S2:1624:4	O
a	TRULICITY.xml:S2:1629:1	O
personal	TRULICITY.xml:S2:1631:8	O
or	TRULICITY.xml:S2:1640:2	O
family	TRULICITY.xml:S2:1643:6	O
history	TRULICITY.xml:S2:1650:7	O
of	TRULICITY.xml:S2:1658:2	O
MTC	TRULICITY.xml:S2:1661:3	O
and	TRULICITY.xml:S2:1665:3	O
in	TRULICITY.xml:S2:1669:2	O
patients	TRULICITY.xml:S2:1672:8	O
with	TRULICITY.xml:S2:1681:4	O
Multiple	TRULICITY.xml:S2:1686:8	O
Endocrine	TRULICITY.xml:S2:1695:9	O
Neoplasia	TRULICITY.xml:S2:1705:9	O
syndrome	TRULICITY.xml:S2:1715:8	O
type	TRULICITY.xml:S2:1724:4	O
2	TRULICITY.xml:S2:1729:1	O
(	TRULICITY.xml:S2:1731:1	O
MEN	TRULICITY.xml:S2:1732:3	O
2	TRULICITY.xml:S2:1736:1	O
)	TRULICITY.xml:S2:1737:1	O
.	TRULICITY.xml:S2:1738:1	O

Counsel	TRULICITY.xml:S2:1740:7	O
patients	TRULICITY.xml:S2:1748:8	O
regarding	TRULICITY.xml:S2:1757:9	O
the	TRULICITY.xml:S2:1767:3	O
potential	TRULICITY.xml:S2:1771:9	O
risk	TRULICITY.xml:S2:1781:4	O
of	TRULICITY.xml:S2:1786:2	O
MTC	TRULICITY.xml:S2:1789:3	O
and	TRULICITY.xml:S2:1793:3	O
symptoms	TRULICITY.xml:S2:1797:8	O
of	TRULICITY.xml:S2:1806:2	O
thyroid	TRULICITY.xml:S2:1809:7	O
tumors	TRULICITY.xml:S2:1817:6	O
(	TRULICITY.xml:S2:1824:1	O
4.1	TRULICITY.xml:S2:1825:3	O
,	TRULICITY.xml:S2:1828:1	O
5.1	TRULICITY.xml:S2:1830:3	O
)	TRULICITY.xml:S2:1833:1	O
.	TRULICITY.xml:S2:1834:1	O
\n	TRULICITY.xml:S2:1836:1	O
5	TRULICITY.xml:S3:4:1	O
WARNINGS	TRULICITY.xml:S3:6:8	O
AND	TRULICITY.xml:S3:15:3	O
PRECAUTIONS	TRULICITY.xml:S3:19:11	O

EXCERPT	TRULICITY.xml:S3:37:7	O
:	TRULICITY.xml:S3:44:1	O
Thyroid	TRULICITY.xml:S3:53:7	B-AdverseReaction
C	TRULICITY.xml:S3:61:1	I-AdverseReaction
-	TRULICITY.xml:S3:62:1	I-AdverseReaction
cell	TRULICITY.xml:S3:63:4	I-AdverseReaction
Tumors	TRULICITY.xml:S3:68:6	I-AdverseReaction
:	TRULICITY.xml:S3:74:1	O
See	TRULICITY.xml:S3:76:3	O
Boxed	TRULICITY.xml:S3:80:5	O
Warning	TRULICITY.xml:S3:86:7	O
(	TRULICITY.xml:S3:94:1	O
5.1	TRULICITY.xml:S3:97:3	O
)	TRULICITY.xml:S3:102:1	O
.	TRULICITY.xml:S3:103:1	O

Pancreatitis	TRULICITY.xml:S3:111:12	B-AdverseReaction
:	TRULICITY.xml:S3:123:1	O
Has	TRULICITY.xml:S3:125:3	O
been	TRULICITY.xml:S3:129:4	O
reported	TRULICITY.xml:S3:134:8	O
in	TRULICITY.xml:S3:143:2	O
clinical	TRULICITY.xml:S3:146:8	O
trials	TRULICITY.xml:S3:155:6	O
.	TRULICITY.xml:S3:161:1	O

Discontinue	TRULICITY.xml:S3:163:11	O
promptly	TRULICITY.xml:S3:175:8	O
if	TRULICITY.xml:S3:184:2	O
pancreatitis	TRULICITY.xml:S3:187:12	O
is	TRULICITY.xml:S3:200:2	O
suspected	TRULICITY.xml:S3:203:9	O
.	TRULICITY.xml:S3:212:1	O

Do	TRULICITY.xml:S3:214:2	O
not	TRULICITY.xml:S3:217:3	O
restart	TRULICITY.xml:S3:221:7	O
if	TRULICITY.xml:S3:229:2	O
pancreatitis	TRULICITY.xml:S3:232:12	O
is	TRULICITY.xml:S3:245:2	O
confirmed	TRULICITY.xml:S3:248:9	O
.	TRULICITY.xml:S3:257:1	O

Consider	TRULICITY.xml:S3:259:8	O
other	TRULICITY.xml:S3:268:5	O
antidiabetic	TRULICITY.xml:S3:274:12	O
therapies	TRULICITY.xml:S3:287:9	O
in	TRULICITY.xml:S3:297:2	O
patients	TRULICITY.xml:S3:300:8	O
with	TRULICITY.xml:S3:309:4	O
history	TRULICITY.xml:S3:314:7	O
of	TRULICITY.xml:S3:322:2	O
pancreatitis	TRULICITY.xml:S3:325:12	O
(	TRULICITY.xml:S3:338:1	O
5.2	TRULICITY.xml:S3:341:3	O
)	TRULICITY.xml:S3:346:1	O
.	TRULICITY.xml:S3:347:1	O

Hypoglycemia	TRULICITY.xml:S3:355:12	B-AdverseReaction
:	TRULICITY.xml:S3:367:1	O
When	TRULICITY.xml:S3:369:4	O
TRULICITY	TRULICITY.xml:S3:374:9	O
is	TRULICITY.xml:S3:384:2	O
used	TRULICITY.xml:S3:387:4	O
with	TRULICITY.xml:S3:392:4	O
an	TRULICITY.xml:S3:397:2	O
insulin	TRULICITY.xml:S3:400:7	O
secretagogue	TRULICITY.xml:S3:408:12	O
(	TRULICITY.xml:S3:421:1	O
e	TRULICITY.xml:S3:422:1	O
.	TRULICITY.xml:S3:423:1	O
g	TRULICITY.xml:S3:424:1	O
.	TRULICITY.xml:S3:425:1	O
,	TRULICITY.xml:S3:426:1	O
a	TRULICITY.xml:S3:428:1	O
sulfonylurea	TRULICITY.xml:S3:430:12	O
)	TRULICITY.xml:S3:442:1	O
or	TRULICITY.xml:S3:444:2	O
insulin	TRULICITY.xml:S3:447:7	O
,	TRULICITY.xml:S3:454:1	O
consider	TRULICITY.xml:S3:456:8	O
lowering	TRULICITY.xml:S3:465:8	O
the	TRULICITY.xml:S3:474:3	O
dose	TRULICITY.xml:S3:478:4	O
of	TRULICITY.xml:S3:483:2	O
the	TRULICITY.xml:S3:486:3	O
sulfonylurea	TRULICITY.xml:S3:490:12	O
or	TRULICITY.xml:S3:503:2	O
insulin	TRULICITY.xml:S3:506:7	O
to	TRULICITY.xml:S3:514:2	O
reduce	TRULICITY.xml:S3:517:6	O
the	TRULICITY.xml:S3:524:3	O
risk	TRULICITY.xml:S3:528:4	O
of	TRULICITY.xml:S3:533:2	O
hypoglycemia	TRULICITY.xml:S3:536:12	O
(	TRULICITY.xml:S3:549:1	O
5.3	TRULICITY.xml:S3:552:3	O
)	TRULICITY.xml:S3:557:1	O
.	TRULICITY.xml:S3:558:1	O

Hypersensitivity	TRULICITY.xml:S3:566:16	B-AdverseReaction
Reactions	TRULICITY.xml:S3:583:9	O
:	TRULICITY.xml:S3:592:1	O
Discontinue	TRULICITY.xml:S3:594:11	O
TRULICITY	TRULICITY.xml:S3:606:9	O
if	TRULICITY.xml:S3:616:2	O
suspected	TRULICITY.xml:S3:619:9	O
.	TRULICITY.xml:S3:628:1	O

Monitor	TRULICITY.xml:S3:630:7	O
and	TRULICITY.xml:S3:638:3	O
treat	TRULICITY.xml:S3:642:5	O
promptly	TRULICITY.xml:S3:648:8	O
per	TRULICITY.xml:S3:657:3	O
standard	TRULICITY.xml:S3:661:8	O
of	TRULICITY.xml:S3:670:2	O
care	TRULICITY.xml:S3:673:4	O
until	TRULICITY.xml:S3:678:5	O
signs	TRULICITY.xml:S3:684:5	O
and	TRULICITY.xml:S3:690:3	O
symptoms	TRULICITY.xml:S3:694:8	O
resolve	TRULICITY.xml:S3:703:7	O
(	TRULICITY.xml:S3:711:1	O
5.4	TRULICITY.xml:S3:714:3	O
)	TRULICITY.xml:S3:719:1	O
.	TRULICITY.xml:S3:720:1	O

Renal	TRULICITY.xml:S3:728:5	B-AdverseReaction
Impairment	TRULICITY.xml:S3:734:10	I-AdverseReaction
:	TRULICITY.xml:S3:744:1	O
Monitor	TRULICITY.xml:S3:746:7	O
renal	TRULICITY.xml:S3:754:5	O
function	TRULICITY.xml:S3:760:8	O
in	TRULICITY.xml:S3:769:2	O
patients	TRULICITY.xml:S3:772:8	O
with	TRULICITY.xml:S3:781:4	O
renal	TRULICITY.xml:S3:786:5	O
impairment	TRULICITY.xml:S3:792:10	O
reporting	TRULICITY.xml:S3:803:9	O
severe	TRULICITY.xml:S3:813:6	O
adverse	TRULICITY.xml:S3:820:7	O
gastrointestinal	TRULICITY.xml:S3:828:16	O
reactions	TRULICITY.xml:S3:845:9	O
(	TRULICITY.xml:S3:855:1	O
5.5	TRULICITY.xml:S3:858:3	O
)	TRULICITY.xml:S3:863:1	O
.	TRULICITY.xml:S3:864:1	O

Macrovascular	TRULICITY.xml:S3:872:13	O
outcomes	TRULICITY.xml:S3:886:8	O
:	TRULICITY.xml:S3:894:1	O
There	TRULICITY.xml:S3:896:5	O
have	TRULICITY.xml:S3:902:4	O
been	TRULICITY.xml:S3:907:4	O
no	TRULICITY.xml:S3:912:2	O
studies	TRULICITY.xml:S3:915:7	O
establishing	TRULICITY.xml:S3:923:12	O
conclusive	TRULICITY.xml:S3:936:10	O
evidence	TRULICITY.xml:S3:947:8	O
of	TRULICITY.xml:S3:956:2	O
macrovascular	TRULICITY.xml:S3:959:13	O
risk	TRULICITY.xml:S3:973:4	O
reduction	TRULICITY.xml:S3:978:9	O
with	TRULICITY.xml:S3:988:4	O
TRULICITY	TRULICITY.xml:S3:993:9	O
or	TRULICITY.xml:S3:1003:2	O
any	TRULICITY.xml:S3:1006:3	O
other	TRULICITY.xml:S3:1010:5	O
antidiabetic	TRULICITY.xml:S3:1016:12	O
drug	TRULICITY.xml:S3:1029:4	O
(	TRULICITY.xml:S3:1034:1	O
5.7	TRULICITY.xml:S3:1037:3	O
)	TRULICITY.xml:S3:1042:1	O
.	TRULICITY.xml:S3:1043:1	O

5.1	TRULICITY.xml:S3:1057:3	O

Risk	TRULICITY.xml:S3:1061:4	O

of	TRULICITY.xml:S3:1066:2	O
Thyroid	TRULICITY.xml:S3:1069:7	O
C	TRULICITY.xml:S3:1077:1	O
-	TRULICITY.xml:S3:1078:1	O
cell	TRULICITY.xml:S3:1079:4	O
Tumors	TRULICITY.xml:S3:1084:6	O

In	TRULICITY.xml:S3:1099:2	O
male	TRULICITY.xml:S3:1102:4	O
and	TRULICITY.xml:S3:1107:3	O
female	TRULICITY.xml:S3:1111:6	O
rats	TRULICITY.xml:S3:1118:4	B-Animal
,	TRULICITY.xml:S3:1122:1	O
dulaglutide	TRULICITY.xml:S3:1124:11	O
causes	TRULICITY.xml:S3:1136:6	O
a	TRULICITY.xml:S3:1143:1	O
dose	TRULICITY.xml:S3:1145:4	O
-	TRULICITY.xml:S3:1149:1	O
related	TRULICITY.xml:S3:1150:7	O
and	TRULICITY.xml:S3:1158:3	O
treatment	TRULICITY.xml:S3:1162:9	O
-	TRULICITY.xml:S3:1171:1	O
duration	TRULICITY.xml:S3:1172:8	O
-	TRULICITY.xml:S3:1180:1	O
dependent	TRULICITY.xml:S3:1181:9	O
increase	TRULICITY.xml:S3:1191:8	O
in	TRULICITY.xml:S3:1200:2	O
the	TRULICITY.xml:S3:1203:3	O
incidence	TRULICITY.xml:S3:1207:9	O
of	TRULICITY.xml:S3:1217:2	O
thyroid	TRULICITY.xml:S3:1220:7	B-AdverseReaction
C	TRULICITY.xml:S3:1228:1	I-AdverseReaction
-	TRULICITY.xml:S3:1229:1	I-AdverseReaction
cell	TRULICITY.xml:S3:1230:4	I-AdverseReaction
tumors	TRULICITY.xml:S3:1235:6	I-AdverseReaction
(	TRULICITY.xml:S3:1242:1	O
adenomas	TRULICITY.xml:S3:1243:8	I-AdverseReaction
and	TRULICITY.xml:S3:1252:3	O
carcinomas	TRULICITY.xml:S3:1256:10	I-AdverseReaction
)	TRULICITY.xml:S3:1266:1	O
after	TRULICITY.xml:S3:1268:5	O
lifetime	TRULICITY.xml:S3:1274:8	O
exposure	TRULICITY.xml:S3:1283:8	O
[	TRULICITY.xml:S3:1292:1	O
see	TRULICITY.xml:S3:1293:3	O
Nonclinical	TRULICITY.xml:S3:1297:11	O
Toxicology	TRULICITY.xml:S3:1309:10	O
(	TRULICITY.xml:S3:1320:1	O
13.1	TRULICITY.xml:S3:1323:4	O
)]	TRULICITY.xml:S3:1329:2	O
.	TRULICITY.xml:S3:1333:1	O

Glucagon	TRULICITY.xml:S3:1335:8	O
-	TRULICITY.xml:S3:1343:1	O
like	TRULICITY.xml:S3:1344:4	O
peptide	TRULICITY.xml:S3:1349:7	O
(	TRULICITY.xml:S3:1357:1	O
GLP	TRULICITY.xml:S3:1358:3	O
-	TRULICITY.xml:S3:1361:1	O
1	TRULICITY.xml:S3:1362:1	O
)	TRULICITY.xml:S3:1363:1	O
receptor	TRULICITY.xml:S3:1365:8	O
agonists	TRULICITY.xml:S3:1374:8	O
have	TRULICITY.xml:S3:1383:4	O
induced	TRULICITY.xml:S3:1388:7	O
thyroid	TRULICITY.xml:S3:1396:7	B-AdverseReaction
C	TRULICITY.xml:S3:1404:1	I-AdverseReaction
-	TRULICITY.xml:S3:1405:1	I-AdverseReaction
cell	TRULICITY.xml:S3:1406:4	I-AdverseReaction
adenomas	TRULICITY.xml:S3:1411:8	I-AdverseReaction
and	TRULICITY.xml:S3:1420:3	O
carcinomas	TRULICITY.xml:S3:1424:10	I-AdverseReaction
in	TRULICITY.xml:S3:1435:2	O
mice	TRULICITY.xml:S3:1438:4	B-Animal
and	TRULICITY.xml:S3:1443:3	O
rats	TRULICITY.xml:S3:1447:4	B-Animal
at	TRULICITY.xml:S3:1452:2	O
clinically	TRULICITY.xml:S3:1455:10	O
relevant	TRULICITY.xml:S3:1466:8	O
exposures	TRULICITY.xml:S3:1475:9	O
.	TRULICITY.xml:S3:1484:1	O

It	TRULICITY.xml:S3:1486:2	O
is	TRULICITY.xml:S3:1489:2	O
unknown	TRULICITY.xml:S3:1492:7	B-Factor
whether	TRULICITY.xml:S3:1500:7	O
TRULICITY	TRULICITY.xml:S3:1508:9	O
will	TRULICITY.xml:S3:1518:4	O
cause	TRULICITY.xml:S3:1523:5	O
thyroid	TRULICITY.xml:S3:1529:7	B-AdverseReaction
C	TRULICITY.xml:S3:1537:1	I-AdverseReaction
-	TRULICITY.xml:S3:1538:1	I-AdverseReaction
cell	TRULICITY.xml:S3:1539:4	I-AdverseReaction
tumors	TRULICITY.xml:S3:1544:6	I-AdverseReaction
,	TRULICITY.xml:S3:1550:1	O
including	TRULICITY.xml:S3:1552:9	O
medullary	TRULICITY.xml:S3:1562:9	B-AdverseReaction
thyroid	TRULICITY.xml:S3:1572:7	I-AdverseReaction
carcinoma	TRULICITY.xml:S3:1580:9	I-AdverseReaction
(	TRULICITY.xml:S3:1590:1	O
MTC	TRULICITY.xml:S3:1591:3	B-AdverseReaction
)	TRULICITY.xml:S3:1594:1	O
,	TRULICITY.xml:S3:1595:1	O
in	TRULICITY.xml:S3:1597:2	O
humans	TRULICITY.xml:S3:1600:6	O
,	TRULICITY.xml:S3:1606:1	O
as	TRULICITY.xml:S3:1608:2	O
the	TRULICITY.xml:S3:1611:3	O
human	TRULICITY.xml:S3:1615:5	O
relevance	TRULICITY.xml:S3:1621:9	O
of	TRULICITY.xml:S3:1631:2	O
dulaglutide	TRULICITY.xml:S3:1634:11	O
-	TRULICITY.xml:S3:1645:1	O
induced	TRULICITY.xml:S3:1646:7	O
rodent	TRULICITY.xml:S3:1654:6	B-Animal
thyroid	TRULICITY.xml:S3:1661:7	B-AdverseReaction
C	TRULICITY.xml:S3:1669:1	I-AdverseReaction
-	TRULICITY.xml:S3:1670:1	I-AdverseReaction
cell	TRULICITY.xml:S3:1671:4	I-AdverseReaction
tumors	TRULICITY.xml:S3:1676:6	I-AdverseReaction
has	TRULICITY.xml:S3:1683:3	O
not	TRULICITY.xml:S3:1687:3	O
been	TRULICITY.xml:S3:1691:4	O
determined	TRULICITY.xml:S3:1696:10	O
.	TRULICITY.xml:S3:1706:1	O

One	TRULICITY.xml:S3:1715:3	O
case	TRULICITY.xml:S3:1719:4	O
of	TRULICITY.xml:S3:1724:2	O
MTC	TRULICITY.xml:S3:1727:3	B-AdverseReaction
was	TRULICITY.xml:S3:1731:3	O
reported	TRULICITY.xml:S3:1735:8	O
in	TRULICITY.xml:S3:1744:2	O
a	TRULICITY.xml:S3:1747:1	O
patient	TRULICITY.xml:S3:1749:7	O
treated	TRULICITY.xml:S3:1757:7	O
with	TRULICITY.xml:S3:1765:4	O
TRULICITY	TRULICITY.xml:S3:1770:9	O
.	TRULICITY.xml:S3:1779:1	O

This	TRULICITY.xml:S3:1781:4	O
patient	TRULICITY.xml:S3:1786:7	O
had	TRULICITY.xml:S3:1794:3	O
pretreatment	TRULICITY.xml:S3:1798:12	O
calcitonin	TRULICITY.xml:S3:1811:10	O
levels	TRULICITY.xml:S3:1822:6	O
approximately	TRULICITY.xml:S3:1829:13	O
8	TRULICITY.xml:S3:1843:1	O
times	TRULICITY.xml:S3:1845:5	O
the	TRULICITY.xml:S3:1851:3	O
upper	TRULICITY.xml:S3:1855:5	O
limit	TRULICITY.xml:S3:1861:5	O
of	TRULICITY.xml:S3:1867:2	O
normal	TRULICITY.xml:S3:1870:6	O
(	TRULICITY.xml:S3:1877:1	O
ULN	TRULICITY.xml:S3:1878:3	O
)	TRULICITY.xml:S3:1881:1	O
.	TRULICITY.xml:S3:1882:1	O

Cases	TRULICITY.xml:S3:1884:5	O
of	TRULICITY.xml:S3:1890:2	O
MTC	TRULICITY.xml:S3:1893:3	B-AdverseReaction
in	TRULICITY.xml:S3:1897:2	O
patients	TRULICITY.xml:S3:1900:8	O
treated	TRULICITY.xml:S3:1909:7	O
with	TRULICITY.xml:S3:1917:4	O
liraglutide	TRULICITY.xml:S3:1922:11	O
,	TRULICITY.xml:S3:1933:1	O
another	TRULICITY.xml:S3:1935:7	O
GLP	TRULICITY.xml:S3:1943:3	B-DrugClass
-	TRULICITY.xml:S3:1946:1	I-DrugClass
1	TRULICITY.xml:S3:1947:1	I-DrugClass
receptor	TRULICITY.xml:S3:1949:8	I-DrugClass
agonist	TRULICITY.xml:S3:1958:7	I-DrugClass
,	TRULICITY.xml:S3:1965:1	O
have	TRULICITY.xml:S3:1967:4	O
been	TRULICITY.xml:S3:1972:4	O
reported	TRULICITY.xml:S3:1977:8	O
in	TRULICITY.xml:S3:1986:2	O
the	TRULICITY.xml:S3:1989:3	O
postmarketing	TRULICITY.xml:S3:1993:13	O
period	TRULICITY.xml:S3:2007:6	O
;	TRULICITY.xml:S3:2013:1	O
the	TRULICITY.xml:S3:2015:3	O
data	TRULICITY.xml:S3:2019:4	O
in	TRULICITY.xml:S3:2024:2	O
these	TRULICITY.xml:S3:2027:5	O
reports	TRULICITY.xml:S3:2033:7	O
are	TRULICITY.xml:S3:2041:3	O
insufficient	TRULICITY.xml:S3:2045:12	O
to	TRULICITY.xml:S3:2058:2	O
establish	TRULICITY.xml:S3:2061:9	O
or	TRULICITY.xml:S3:2071:2	O
exclude	TRULICITY.xml:S3:2074:7	O
a	TRULICITY.xml:S3:2082:1	O
causal	TRULICITY.xml:S3:2084:6	O
relationship	TRULICITY.xml:S3:2091:12	O
between	TRULICITY.xml:S3:2104:7	O
MTC	TRULICITY.xml:S3:2112:3	B-AdverseReaction
and	TRULICITY.xml:S3:2116:3	O
GLP	TRULICITY.xml:S3:2120:3	O
-	TRULICITY.xml:S3:2123:1	O
1	TRULICITY.xml:S3:2124:1	O
receptor	TRULICITY.xml:S3:2126:8	O
agonist	TRULICITY.xml:S3:2135:7	O
use	TRULICITY.xml:S3:2143:3	O
in	TRULICITY.xml:S3:2147:2	O
humans	TRULICITY.xml:S3:2150:6	O
.	TRULICITY.xml:S3:2156:1	O

TRULICITY	TRULICITY.xml:S3:2165:9	O
is	TRULICITY.xml:S3:2175:2	O
contraindicated	TRULICITY.xml:S3:2178:15	O
in	TRULICITY.xml:S3:2194:2	O
patients	TRULICITY.xml:S3:2197:8	O
with	TRULICITY.xml:S3:2206:4	O
a	TRULICITY.xml:S3:2211:1	O
personal	TRULICITY.xml:S3:2213:8	O
or	TRULICITY.xml:S3:2222:2	O
family	TRULICITY.xml:S3:2225:6	O
history	TRULICITY.xml:S3:2232:7	O
of	TRULICITY.xml:S3:2240:2	O
MTC	TRULICITY.xml:S3:2243:3	O
or	TRULICITY.xml:S3:2247:2	O
in	TRULICITY.xml:S3:2250:2	O
patients	TRULICITY.xml:S3:2253:8	O
with	TRULICITY.xml:S3:2262:4	O
MEN	TRULICITY.xml:S3:2267:3	O
2	TRULICITY.xml:S3:2271:1	O
.	TRULICITY.xml:S3:2272:1	O

Counsel	TRULICITY.xml:S3:2274:7	O
patients	TRULICITY.xml:S3:2282:8	O
regarding	TRULICITY.xml:S3:2291:9	O
the	TRULICITY.xml:S3:2301:3	O
potential	TRULICITY.xml:S3:2305:9	O
risk	TRULICITY.xml:S3:2315:4	O
for	TRULICITY.xml:S3:2320:3	O
MTC	TRULICITY.xml:S3:2324:3	O
with	TRULICITY.xml:S3:2328:4	O
the	TRULICITY.xml:S3:2333:3	O
use	TRULICITY.xml:S3:2337:3	O
of	TRULICITY.xml:S3:2341:2	O
TRULICITY	TRULICITY.xml:S3:2344:9	O
and	TRULICITY.xml:S3:2354:3	O
inform	TRULICITY.xml:S3:2358:6	O
them	TRULICITY.xml:S3:2365:4	O
of	TRULICITY.xml:S3:2370:2	O
symptoms	TRULICITY.xml:S3:2373:8	O
of	TRULICITY.xml:S3:2382:2	O
thyroid	TRULICITY.xml:S3:2385:7	O
tumors	TRULICITY.xml:S3:2393:6	O
(	TRULICITY.xml:S3:2400:1	O
e	TRULICITY.xml:S3:2401:1	O
.	TRULICITY.xml:S3:2402:1	O
g	TRULICITY.xml:S3:2403:1	O
.	TRULICITY.xml:S3:2404:1	O

a	TRULICITY.xml:S3:2406:1	O
mass	TRULICITY.xml:S3:2408:4	O
in	TRULICITY.xml:S3:2413:2	O
the	TRULICITY.xml:S3:2416:3	O
neck	TRULICITY.xml:S3:2420:4	O
,	TRULICITY.xml:S3:2424:1	O
dysphagia	TRULICITY.xml:S3:2426:9	O
,	TRULICITY.xml:S3:2435:1	O
dyspnea	TRULICITY.xml:S3:2437:7	O
,	TRULICITY.xml:S3:2444:1	O
persistent	TRULICITY.xml:S3:2446:10	O
hoarseness	TRULICITY.xml:S3:2457:10	O
)	TRULICITY.xml:S3:2467:1	O
.	TRULICITY.xml:S3:2468:1	O

Routine	TRULICITY.xml:S3:2477:7	O
monitoring	TRULICITY.xml:S3:2485:10	O
of	TRULICITY.xml:S3:2496:2	O
serum	TRULICITY.xml:S3:2499:5	O
calcitonin	TRULICITY.xml:S3:2505:10	O
or	TRULICITY.xml:S3:2516:2	O
using	TRULICITY.xml:S3:2519:5	O
thyroid	TRULICITY.xml:S3:2525:7	O
ultrasound	TRULICITY.xml:S3:2533:10	O
is	TRULICITY.xml:S3:2544:2	O
of	TRULICITY.xml:S3:2547:2	O
uncertain	TRULICITY.xml:S3:2550:9	O
value	TRULICITY.xml:S3:2560:5	O
for	TRULICITY.xml:S3:2566:3	O
early	TRULICITY.xml:S3:2570:5	O
detection	TRULICITY.xml:S3:2576:9	O
of	TRULICITY.xml:S3:2586:2	O
MTC	TRULICITY.xml:S3:2589:3	O
in	TRULICITY.xml:S3:2593:2	O
patients	TRULICITY.xml:S3:2596:8	O
treated	TRULICITY.xml:S3:2605:7	O
with	TRULICITY.xml:S3:2613:4	O
TRULICITY	TRULICITY.xml:S3:2618:9	O
.	TRULICITY.xml:S3:2627:1	O

Such	TRULICITY.xml:S3:2629:4	O
monitoring	TRULICITY.xml:S3:2634:10	O
may	TRULICITY.xml:S3:2645:3	O
increase	TRULICITY.xml:S3:2649:8	O
the	TRULICITY.xml:S3:2658:3	O
risk	TRULICITY.xml:S3:2662:4	O
of	TRULICITY.xml:S3:2667:2	O
unnecessary	TRULICITY.xml:S3:2670:11	O
procedures	TRULICITY.xml:S3:2682:10	O
,	TRULICITY.xml:S3:2692:1	O
due	TRULICITY.xml:S3:2694:3	O
to	TRULICITY.xml:S3:2698:2	O
the	TRULICITY.xml:S3:2701:3	O
low	TRULICITY.xml:S3:2705:3	O
test	TRULICITY.xml:S3:2709:4	O
specificity	TRULICITY.xml:S3:2714:11	O
for	TRULICITY.xml:S3:2726:3	O
serum	TRULICITY.xml:S3:2730:5	O
calcitonin	TRULICITY.xml:S3:2736:10	O
and	TRULICITY.xml:S3:2747:3	O
a	TRULICITY.xml:S3:2751:1	O
high	TRULICITY.xml:S3:2753:4	O
background	TRULICITY.xml:S3:2758:10	O
incidence	TRULICITY.xml:S3:2769:9	O
of	TRULICITY.xml:S3:2779:2	O
thyroid	TRULICITY.xml:S3:2782:7	O
disease	TRULICITY.xml:S3:2790:7	O
.	TRULICITY.xml:S3:2797:1	O

Significantly	TRULICITY.xml:S3:2799:13	O
elevated	TRULICITY.xml:S3:2813:8	O
serum	TRULICITY.xml:S3:2822:5	O
calcitonin	TRULICITY.xml:S3:2828:10	O
value	TRULICITY.xml:S3:2839:5	O
may	TRULICITY.xml:S3:2845:3	O
indicate	TRULICITY.xml:S3:2849:8	O
MTC	TRULICITY.xml:S3:2858:3	O
and	TRULICITY.xml:S3:2862:3	O
patients	TRULICITY.xml:S3:2866:8	O
with	TRULICITY.xml:S3:2875:4	O
MTC	TRULICITY.xml:S3:2880:3	O
usually	TRULICITY.xml:S3:2884:7	O
have	TRULICITY.xml:S3:2892:4	O
calcitonin	TRULICITY.xml:S3:2897:10	O
values	TRULICITY.xml:S3:2908:6	O
50	TRULICITY.xml:S3:2916:2	O
ng	TRULICITY.xml:S3:2919:2	O
L.	TRULICITY.xml:S3:2922:2	O

If	TRULICITY.xml:S3:2925:2	O
serum	TRULICITY.xml:S3:2928:5	O
calcitonin	TRULICITY.xml:S3:2934:10	O
is	TRULICITY.xml:S3:2945:2	O
measured	TRULICITY.xml:S3:2948:8	O
and	TRULICITY.xml:S3:2957:3	O
found	TRULICITY.xml:S3:2961:5	O
to	TRULICITY.xml:S3:2967:2	O
be	TRULICITY.xml:S3:2970:2	O
elevated	TRULICITY.xml:S3:2973:8	O
,	TRULICITY.xml:S3:2981:1	O
the	TRULICITY.xml:S3:2983:3	O
patient	TRULICITY.xml:S3:2987:7	O
should	TRULICITY.xml:S3:2995:6	O
be	TRULICITY.xml:S3:3002:2	O
further	TRULICITY.xml:S3:3005:7	O
evaluated	TRULICITY.xml:S3:3013:9	O
.	TRULICITY.xml:S3:3022:1	O

Patients	TRULICITY.xml:S3:3024:8	O
with	TRULICITY.xml:S3:3033:4	O
thyroid	TRULICITY.xml:S3:3038:7	O
nodules	TRULICITY.xml:S3:3046:7	O
noted	TRULICITY.xml:S3:3054:5	O
on	TRULICITY.xml:S3:3060:2	O
physical	TRULICITY.xml:S3:3063:8	O
examination	TRULICITY.xml:S3:3072:11	O
or	TRULICITY.xml:S3:3084:2	O
neck	TRULICITY.xml:S3:3087:4	O
imaging	TRULICITY.xml:S3:3092:7	O
should	TRULICITY.xml:S3:3100:6	O
also	TRULICITY.xml:S3:3107:4	O
be	TRULICITY.xml:S3:3112:2	O
further	TRULICITY.xml:S3:3115:7	O
evaluated	TRULICITY.xml:S3:3123:9	O
.	TRULICITY.xml:S3:3132:1	O

5.2	TRULICITY.xml:S3:3141:3	O
Pancreatitis	TRULICITY.xml:S3:3145:12	O

In	TRULICITY.xml:S3:3163:2	O
Phase	TRULICITY.xml:S3:3166:5	O
2	TRULICITY.xml:S3:3172:1	O
and	TRULICITY.xml:S3:3174:3	O
Phase	TRULICITY.xml:S3:3178:5	O
3	TRULICITY.xml:S3:3184:1	O
clinical	TRULICITY.xml:S3:3186:8	O
studies	TRULICITY.xml:S3:3195:7	O
,	TRULICITY.xml:S3:3202:1	O
12	TRULICITY.xml:S3:3204:2	O
(	TRULICITY.xml:S3:3207:1	O
3.4	TRULICITY.xml:S3:3208:3	O
cases	TRULICITY.xml:S3:3212:5	O
per	TRULICITY.xml:S3:3218:3	O
1000	TRULICITY.xml:S3:3222:4	O
patient	TRULICITY.xml:S3:3227:7	O
years	TRULICITY.xml:S3:3235:5	O
)	TRULICITY.xml:S3:3240:1	O
pancreatitis	TRULICITY.xml:S3:3242:12	B-AdverseReaction
related	TRULICITY.xml:S3:3255:7	O
adverse	TRULICITY.xml:S3:3263:7	O
reactions	TRULICITY.xml:S3:3271:9	O
were	TRULICITY.xml:S3:3281:4	O
reported	TRULICITY.xml:S3:3286:8	O
in	TRULICITY.xml:S3:3295:2	O
patients	TRULICITY.xml:S3:3298:8	O
exposed	TRULICITY.xml:S3:3307:7	O
to	TRULICITY.xml:S3:3315:2	O
TRULICITY	TRULICITY.xml:S3:3318:9	O
versus	TRULICITY.xml:S3:3328:6	O
3	TRULICITY.xml:S3:3335:1	O
in	TRULICITY.xml:S3:3337:2	O
non	TRULICITY.xml:S3:3340:3	O
-	TRULICITY.xml:S3:3343:1	O
incretin	TRULICITY.xml:S3:3344:8	O
comparators	TRULICITY.xml:S3:3353:11	O
(	TRULICITY.xml:S3:3365:1	O
2.7	TRULICITY.xml:S3:3366:3	O
cases	TRULICITY.xml:S3:3370:5	O
per	TRULICITY.xml:S3:3376:3	O
1000	TRULICITY.xml:S3:3380:4	O
patient	TRULICITY.xml:S3:3385:7	O
years	TRULICITY.xml:S3:3393:5	O
)	TRULICITY.xml:S3:3398:1	O
.	TRULICITY.xml:S3:3399:1	O

An	TRULICITY.xml:S3:3401:2	O
analyses	TRULICITY.xml:S3:3404:8	O
of	TRULICITY.xml:S3:3413:2	O
adjudicated	TRULICITY.xml:S3:3416:11	O
events	TRULICITY.xml:S3:3428:6	O
revealed	TRULICITY.xml:S3:3435:8	O
5	TRULICITY.xml:S3:3444:1	O
cases	TRULICITY.xml:S3:3446:5	O
of	TRULICITY.xml:S3:3452:2	O
confirmed	TRULICITY.xml:S3:3455:9	O
pancreatitis	TRULICITY.xml:S3:3465:12	B-AdverseReaction
in	TRULICITY.xml:S3:3478:2	O
patients	TRULICITY.xml:S3:3481:8	O
exposed	TRULICITY.xml:S3:3490:7	O
to	TRULICITY.xml:S3:3498:2	O
TRULICITY	TRULICITY.xml:S3:3501:9	O
(	TRULICITY.xml:S3:3511:1	O
1.4	TRULICITY.xml:S3:3512:3	O
cases	TRULICITY.xml:S3:3516:5	O
per	TRULICITY.xml:S3:3522:3	O
1000	TRULICITY.xml:S3:3526:4	O
patient	TRULICITY.xml:S3:3531:7	O
years	TRULICITY.xml:S3:3539:5	O
)	TRULICITY.xml:S3:3544:1	O
versus	TRULICITY.xml:S3:3546:6	O
1	TRULICITY.xml:S3:3553:1	O
case	TRULICITY.xml:S3:3555:4	O
in	TRULICITY.xml:S3:3560:2	O
non	TRULICITY.xml:S3:3563:3	O
-	TRULICITY.xml:S3:3566:1	O
incretin	TRULICITY.xml:S3:3567:8	O
comparators	TRULICITY.xml:S3:3576:11	O
(	TRULICITY.xml:S3:3588:1	O
0.88	TRULICITY.xml:S3:3589:4	O
cases	TRULICITY.xml:S3:3594:5	O
per	TRULICITY.xml:S3:3600:3	O
1000	TRULICITY.xml:S3:3604:4	O
patient	TRULICITY.xml:S3:3609:7	O
years	TRULICITY.xml:S3:3617:5	O
)	TRULICITY.xml:S3:3622:1	O
.	TRULICITY.xml:S3:3623:1	O

After	TRULICITY.xml:S3:3629:5	O
initiation	TRULICITY.xml:S3:3635:10	O
of	TRULICITY.xml:S3:3646:2	O
TRULICITY	TRULICITY.xml:S3:3649:9	O
,	TRULICITY.xml:S3:3658:1	O
observe	TRULICITY.xml:S3:3660:7	O
patients	TRULICITY.xml:S3:3668:8	O
carefully	TRULICITY.xml:S3:3677:9	O
for	TRULICITY.xml:S3:3687:3	O
signs	TRULICITY.xml:S3:3691:5	O
and	TRULICITY.xml:S3:3697:3	O
symptoms	TRULICITY.xml:S3:3701:8	O
of	TRULICITY.xml:S3:3710:2	O
pancreatitis	TRULICITY.xml:S3:3713:12	O
,	TRULICITY.xml:S3:3725:1	O
including	TRULICITY.xml:S3:3727:9	O
persistent	TRULICITY.xml:S3:3737:10	O
severe	TRULICITY.xml:S3:3748:6	O
abdominal	TRULICITY.xml:S3:3755:9	O
pain	TRULICITY.xml:S3:3765:4	O
.	TRULICITY.xml:S3:3769:1	O

If	TRULICITY.xml:S3:3771:2	O
pancreatitis	TRULICITY.xml:S3:3774:12	O
is	TRULICITY.xml:S3:3787:2	O
suspected	TRULICITY.xml:S3:3790:9	O
,	TRULICITY.xml:S3:3799:1	O
promptly	TRULICITY.xml:S3:3801:8	O
discontinue	TRULICITY.xml:S3:3810:11	O
TRULICITY	TRULICITY.xml:S3:3822:9	O
.	TRULICITY.xml:S3:3831:1	O

If	TRULICITY.xml:S3:3833:2	O
pancreatitis	TRULICITY.xml:S3:3836:12	O
is	TRULICITY.xml:S3:3849:2	O
confirmed	TRULICITY.xml:S3:3852:9	O
,	TRULICITY.xml:S3:3861:1	O
TRULICITY	TRULICITY.xml:S3:3863:9	O
should	TRULICITY.xml:S3:3873:6	O
not	TRULICITY.xml:S3:3880:3	O
be	TRULICITY.xml:S3:3884:2	O
restarted	TRULICITY.xml:S3:3887:9	O
.	TRULICITY.xml:S3:3896:1	O

TRULICITY	TRULICITY.xml:S3:3898:9	O
has	TRULICITY.xml:S3:3908:3	O
not	TRULICITY.xml:S3:3912:3	O
been	TRULICITY.xml:S3:3916:4	O
evaluated	TRULICITY.xml:S3:3921:9	O
in	TRULICITY.xml:S3:3931:2	O
patients	TRULICITY.xml:S3:3934:8	O
with	TRULICITY.xml:S3:3943:4	O
a	TRULICITY.xml:S3:3948:1	O
prior	TRULICITY.xml:S3:3950:5	O
history	TRULICITY.xml:S3:3956:7	O
of	TRULICITY.xml:S3:3964:2	O
pancreatitis	TRULICITY.xml:S3:3967:12	O
.	TRULICITY.xml:S3:3979:1	O

Consider	TRULICITY.xml:S3:3981:8	O
other	TRULICITY.xml:S3:3990:5	O
antidiabetic	TRULICITY.xml:S3:3996:12	O
therapies	TRULICITY.xml:S3:4009:9	O
in	TRULICITY.xml:S3:4019:2	O
patients	TRULICITY.xml:S3:4022:8	O
with	TRULICITY.xml:S3:4031:4	O
a	TRULICITY.xml:S3:4036:1	O
history	TRULICITY.xml:S3:4038:7	O
of	TRULICITY.xml:S3:4046:2	O
pancreatitis	TRULICITY.xml:S3:4049:12	O
.	TRULICITY.xml:S3:4061:1	O

5.3	TRULICITY.xml:S3:4070:3	O
Hypoglycemia	TRULICITY.xml:S3:4074:12	O
with	TRULICITY.xml:S3:4087:4	O
Concomitant	TRULICITY.xml:S3:4092:11	O
Use	TRULICITY.xml:S3:4104:3	O
of	TRULICITY.xml:S3:4108:2	O
Insulin	TRULICITY.xml:S3:4111:7	O
Secretagogues	TRULICITY.xml:S3:4119:13	O
or	TRULICITY.xml:S3:4133:2	O
Insulin	TRULICITY.xml:S3:4136:7	O

The	TRULICITY.xml:S3:4149:3	O
risk	TRULICITY.xml:S3:4153:4	B-Factor
of	TRULICITY.xml:S3:4158:2	O
hypoglycemia	TRULICITY.xml:S3:4161:12	B-AdverseReaction
is	TRULICITY.xml:S3:4174:2	O
increased	TRULICITY.xml:S3:4177:9	O
when	TRULICITY.xml:S3:4187:4	O
TRULICITY	TRULICITY.xml:S3:4192:9	O
is	TRULICITY.xml:S3:4202:2	O
used	TRULICITY.xml:S3:4205:4	O
in	TRULICITY.xml:S3:4210:2	O
combination	TRULICITY.xml:S3:4213:11	O
with	TRULICITY.xml:S3:4225:4	O
insulin	TRULICITY.xml:S3:4230:7	O
secretagogues	TRULICITY.xml:S3:4238:13	O
(	TRULICITY.xml:S3:4252:1	O
e	TRULICITY.xml:S3:4253:1	O
.	TRULICITY.xml:S3:4254:1	O
g	TRULICITY.xml:S3:4255:1	O
.	TRULICITY.xml:S3:4256:1	O
,	TRULICITY.xml:S3:4257:1	O
sulfonylureas	TRULICITY.xml:S3:4259:13	O
)	TRULICITY.xml:S3:4272:1	O
or	TRULICITY.xml:S3:4274:2	O
insulin	TRULICITY.xml:S3:4277:7	O
.	TRULICITY.xml:S3:4284:1	O

Patients	TRULICITY.xml:S3:4286:8	O
may	TRULICITY.xml:S3:4295:3	O
require	TRULICITY.xml:S3:4299:7	O
a	TRULICITY.xml:S3:4307:1	O
lower	TRULICITY.xml:S3:4309:5	O
dose	TRULICITY.xml:S3:4315:4	O
of	TRULICITY.xml:S3:4320:2	O
sulfonylurea	TRULICITY.xml:S3:4323:12	O
or	TRULICITY.xml:S3:4336:2	O
insulin	TRULICITY.xml:S3:4339:7	O
to	TRULICITY.xml:S3:4347:2	O
reduce	TRULICITY.xml:S3:4350:6	O
the	TRULICITY.xml:S3:4357:3	O
risk	TRULICITY.xml:S3:4361:4	O
of	TRULICITY.xml:S3:4366:2	O
hypoglycemia	TRULICITY.xml:S3:4369:12	O
in	TRULICITY.xml:S3:4382:2	O
this	TRULICITY.xml:S3:4385:4	O
setting	TRULICITY.xml:S3:4390:7	O
[	TRULICITY.xml:S3:4398:1	O
see	TRULICITY.xml:S3:4399:3	O
Adverse	TRULICITY.xml:S3:4403:7	O
Reactions	TRULICITY.xml:S3:4411:9	O
(	TRULICITY.xml:S3:4421:1	O
6.1	TRULICITY.xml:S3:4424:3	O
)]	TRULICITY.xml:S3:4429:2	O
.	TRULICITY.xml:S3:4433:1	O

5.4	TRULICITY.xml:S3:4442:3	O
Hypersensitivity	TRULICITY.xml:S3:4446:16	O
Reactions	TRULICITY.xml:S3:4463:9	O

Systemic	TRULICITY.xml:S3:4478:8	B-AdverseReaction
hypersensitivity	TRULICITY.xml:S3:4487:16	I-AdverseReaction
reactions	TRULICITY.xml:S3:4504:9	O
were	TRULICITY.xml:S3:4514:4	O
observed	TRULICITY.xml:S3:4519:8	O
in	TRULICITY.xml:S3:4528:2	O
patients	TRULICITY.xml:S3:4531:8	O
receiving	TRULICITY.xml:S3:4540:9	O
TRULICITY	TRULICITY.xml:S3:4550:9	O
in	TRULICITY.xml:S3:4560:2	O
clinical	TRULICITY.xml:S3:4563:8	O
trials	TRULICITY.xml:S3:4572:6	O
[	TRULICITY.xml:S3:4579:1	O
see	TRULICITY.xml:S3:4580:3	O
Adverse	TRULICITY.xml:S3:4584:7	O
Reactions	TRULICITY.xml:S3:4592:9	O
(	TRULICITY.xml:S3:4602:1	O
6.1	TRULICITY.xml:S3:4605:3	O
)]	TRULICITY.xml:S3:4610:2	O
.	TRULICITY.xml:S3:4612:1	O

If	TRULICITY.xml:S3:4615:2	O
a	TRULICITY.xml:S3:4618:1	O
hypersensitivity	TRULICITY.xml:S3:4620:16	O
reaction	TRULICITY.xml:S3:4637:8	O
occurs	TRULICITY.xml:S3:4646:6	O
,	TRULICITY.xml:S3:4652:1	O
the	TRULICITY.xml:S3:4654:3	O
patient	TRULICITY.xml:S3:4658:7	O
should	TRULICITY.xml:S3:4666:6	O
discontinue	TRULICITY.xml:S3:4673:11	O
TRULICITY	TRULICITY.xml:S3:4685:9	O
and	TRULICITY.xml:S3:4695:3	O
promptly	TRULICITY.xml:S3:4699:8	O
seek	TRULICITY.xml:S3:4708:4	O
medical	TRULICITY.xml:S3:4713:7	O
advice	TRULICITY.xml:S3:4721:6	O
.	TRULICITY.xml:S3:4727:1	O

5.5	TRULICITY.xml:S3:4736:3	O
Renal	TRULICITY.xml:S3:4740:5	O
Impairment	TRULICITY.xml:S3:4746:10	O

In	TRULICITY.xml:S3:4762:2	O
patients	TRULICITY.xml:S3:4765:8	O
treated	TRULICITY.xml:S3:4774:7	O
with	TRULICITY.xml:S3:4782:4	O
GLP	TRULICITY.xml:S3:4787:3	B-DrugClass
-	TRULICITY.xml:S3:4790:1	I-DrugClass
1	TRULICITY.xml:S3:4791:1	I-DrugClass
receptor	TRULICITY.xml:S3:4793:8	I-DrugClass
agonists	TRULICITY.xml:S3:4802:8	I-DrugClass
,	TRULICITY.xml:S3:4810:1	O
there	TRULICITY.xml:S3:4812:5	O
have	TRULICITY.xml:S3:4818:4	O
been	TRULICITY.xml:S3:4823:4	O
postmarketing	TRULICITY.xml:S3:4828:13	O
reports	TRULICITY.xml:S3:4842:7	O
of	TRULICITY.xml:S3:4850:2	O
acute	TRULICITY.xml:S3:4853:5	B-AdverseReaction
renal	TRULICITY.xml:S3:4859:5	I-AdverseReaction
failure	TRULICITY.xml:S3:4865:7	I-AdverseReaction
and	TRULICITY.xml:S3:4873:3	O
worsening	TRULICITY.xml:S3:4877:9	O
of	TRULICITY.xml:S3:4887:2	O
chronic	TRULICITY.xml:S3:4890:7	B-AdverseReaction
renal	TRULICITY.xml:S3:4898:5	I-AdverseReaction
failure	TRULICITY.xml:S3:4904:7	I-AdverseReaction
,	TRULICITY.xml:S3:4911:1	O
which	TRULICITY.xml:S3:4913:5	O
may	TRULICITY.xml:S3:4919:3	O
sometimes	TRULICITY.xml:S3:4923:9	O
require	TRULICITY.xml:S3:4933:7	O
hemodialysis	TRULICITY.xml:S3:4941:12	O
.	TRULICITY.xml:S3:4953:1	O

Some	TRULICITY.xml:S3:4955:4	O
of	TRULICITY.xml:S3:4960:2	O
these	TRULICITY.xml:S3:4963:5	O
events	TRULICITY.xml:S3:4969:6	O
were	TRULICITY.xml:S3:4976:4	O
reported	TRULICITY.xml:S3:4981:8	O
in	TRULICITY.xml:S3:4990:2	O
patients	TRULICITY.xml:S3:4993:8	O
without	TRULICITY.xml:S3:5002:7	O
known	TRULICITY.xml:S3:5010:5	O
underlying	TRULICITY.xml:S3:5016:10	O
renal	TRULICITY.xml:S3:5027:5	O
disease	TRULICITY.xml:S3:5033:7	O
.	TRULICITY.xml:S3:5040:1	O

A	TRULICITY.xml:S3:5042:1	O
majority	TRULICITY.xml:S3:5044:8	O
of	TRULICITY.xml:S3:5053:2	O
reported	TRULICITY.xml:S3:5056:8	O
events	TRULICITY.xml:S3:5065:6	O
occurred	TRULICITY.xml:S3:5072:8	O
in	TRULICITY.xml:S3:5081:2	O
patients	TRULICITY.xml:S3:5084:8	O
who	TRULICITY.xml:S3:5093:3	O
had	TRULICITY.xml:S3:5097:3	O
experienced	TRULICITY.xml:S3:5101:11	O
nausea	TRULICITY.xml:S3:5113:6	B-AdverseReaction
,	TRULICITY.xml:S3:5119:1	O
vomiting	TRULICITY.xml:S3:5121:8	B-AdverseReaction
,	TRULICITY.xml:S3:5129:1	O
diarrhea	TRULICITY.xml:S3:5131:8	B-AdverseReaction
,	TRULICITY.xml:S3:5139:1	O
or	TRULICITY.xml:S3:5141:2	O
dehydration	TRULICITY.xml:S3:5144:11	B-AdverseReaction
.	TRULICITY.xml:S3:5155:1	O

Because	TRULICITY.xml:S3:5157:7	O
these	TRULICITY.xml:S3:5165:5	O
reactions	TRULICITY.xml:S3:5171:9	O
may	TRULICITY.xml:S3:5181:3	O
worsen	TRULICITY.xml:S3:5185:6	O
renal	TRULICITY.xml:S3:5192:5	O
function	TRULICITY.xml:S3:5198:8	O
,	TRULICITY.xml:S3:5206:1	O
use	TRULICITY.xml:S3:5208:3	O
caution	TRULICITY.xml:S3:5212:7	O
when	TRULICITY.xml:S3:5220:4	O
initiating	TRULICITY.xml:S3:5225:10	O
or	TRULICITY.xml:S3:5236:2	O
escalating	TRULICITY.xml:S3:5239:10	O
doses	TRULICITY.xml:S3:5250:5	O
of	TRULICITY.xml:S3:5256:2	O
TRULICITY	TRULICITY.xml:S3:5259:9	O
in	TRULICITY.xml:S3:5269:2	O
patients	TRULICITY.xml:S3:5272:8	O
with	TRULICITY.xml:S3:5281:4	O
renal	TRULICITY.xml:S3:5286:5	O
impairment	TRULICITY.xml:S3:5292:10	O
.	TRULICITY.xml:S3:5302:1	O

Monitor	TRULICITY.xml:S3:5304:7	O
renal	TRULICITY.xml:S3:5312:5	O
function	TRULICITY.xml:S3:5318:8	O
in	TRULICITY.xml:S3:5327:2	O
patients	TRULICITY.xml:S3:5330:8	O
with	TRULICITY.xml:S3:5339:4	O
renal	TRULICITY.xml:S3:5344:5	O
impairment	TRULICITY.xml:S3:5350:10	O
reporting	TRULICITY.xml:S3:5361:9	O
severe	TRULICITY.xml:S3:5371:6	O
adverse	TRULICITY.xml:S3:5378:7	O
gastrointestinal	TRULICITY.xml:S3:5386:16	O
reactions	TRULICITY.xml:S3:5403:9	O
[	TRULICITY.xml:S3:5413:1	O
see	TRULICITY.xml:S3:5414:3	O
Dosage	TRULICITY.xml:S3:5418:6	O
and	TRULICITY.xml:S3:5425:3	O
Administration	TRULICITY.xml:S3:5429:14	O
(	TRULICITY.xml:S3:5444:1	O
2.3	TRULICITY.xml:S3:5447:3	O
)	TRULICITY.xml:S3:5452:1	O
,	TRULICITY.xml:S3:5453:1	O
Use	TRULICITY.xml:S3:5455:3	O
in	TRULICITY.xml:S3:5459:2	O
Specific	TRULICITY.xml:S3:5462:8	O
Populations	TRULICITY.xml:S3:5471:11	O
(	TRULICITY.xml:S3:5483:1	O
8.7	TRULICITY.xml:S3:5486:3	O
)]	TRULICITY.xml:S3:5491:2	O
.	TRULICITY.xml:S3:5493:1	O

5.6	TRULICITY.xml:S3:5504:3	O
Severe	TRULICITY.xml:S3:5508:6	O
Gastrointestinal	TRULICITY.xml:S3:5515:16	O
Disease	TRULICITY.xml:S3:5532:7	O

Use	TRULICITY.xml:S3:5545:3	O
of	TRULICITY.xml:S3:5549:2	O
TRULICITY	TRULICITY.xml:S3:5552:9	O
may	TRULICITY.xml:S3:5562:3	O
be	TRULICITY.xml:S3:5566:2	O
associated	TRULICITY.xml:S3:5569:10	O
with	TRULICITY.xml:S3:5580:4	O
gastrointestinal	TRULICITY.xml:S3:5585:16	B-AdverseReaction
adverse	TRULICITY.xml:S3:5602:7	I-AdverseReaction
reactions	TRULICITY.xml:S3:5610:9	I-AdverseReaction
,	TRULICITY.xml:S3:5619:1	O
sometimes	TRULICITY.xml:S3:5621:9	O
severe	TRULICITY.xml:S3:5631:6	B-Severity
[	TRULICITY.xml:S3:5638:1	O
see	TRULICITY.xml:S3:5639:3	O
Adverse	TRULICITY.xml:S3:5643:7	O
Reactions	TRULICITY.xml:S3:5651:9	O
(	TRULICITY.xml:S3:5661:1	O
6.1	TRULICITY.xml:S3:5664:3	O
)]	TRULICITY.xml:S3:5669:2	O
.	TRULICITY.xml:S3:5673:1	O

TRULICITY	TRULICITY.xml:S3:5675:9	O
has	TRULICITY.xml:S3:5685:3	O
not	TRULICITY.xml:S3:5689:3	O
been	TRULICITY.xml:S3:5693:4	O
studied	TRULICITY.xml:S3:5698:7	O
in	TRULICITY.xml:S3:5706:2	O
patients	TRULICITY.xml:S3:5709:8	O
with	TRULICITY.xml:S3:5718:4	O
severe	TRULICITY.xml:S3:5723:6	O
gastrointestinal	TRULICITY.xml:S3:5730:16	O
disease	TRULICITY.xml:S3:5747:7	O
,	TRULICITY.xml:S3:5754:1	O
including	TRULICITY.xml:S3:5756:9	O
severe	TRULICITY.xml:S3:5766:6	O
gastroparesis	TRULICITY.xml:S3:5773:13	O
,	TRULICITY.xml:S3:5786:1	O
and	TRULICITY.xml:S3:5788:3	O
is	TRULICITY.xml:S3:5792:2	O
therefore	TRULICITY.xml:S3:5795:9	O
not	TRULICITY.xml:S3:5805:3	O
recommended	TRULICITY.xml:S3:5809:11	O
in	TRULICITY.xml:S3:5821:2	O
these	TRULICITY.xml:S3:5824:5	O
patients	TRULICITY.xml:S3:5830:8	O
.	TRULICITY.xml:S3:5838:1	O

5.7	TRULICITY.xml:S3:5847:3	O
Macrovascular	TRULICITY.xml:S3:5851:13	O
Outcomes	TRULICITY.xml:S3:5865:8	O

There	TRULICITY.xml:S3:5879:5	O
have	TRULICITY.xml:S3:5885:4	O
been	TRULICITY.xml:S3:5890:4	O
no	TRULICITY.xml:S3:5895:2	O
clinical	TRULICITY.xml:S3:5898:8	O
studies	TRULICITY.xml:S3:5907:7	O
establishing	TRULICITY.xml:S3:5915:12	O
conclusive	TRULICITY.xml:S3:5928:10	O
evidence	TRULICITY.xml:S3:5939:8	O
of	TRULICITY.xml:S3:5948:2	O
macrovascular	TRULICITY.xml:S3:5951:13	O
risk	TRULICITY.xml:S3:5965:4	O
reduction	TRULICITY.xml:S3:5970:9	O
with	TRULICITY.xml:S3:5980:4	O
TRULICITY	TRULICITY.xml:S3:5985:9	O
or	TRULICITY.xml:S3:5995:2	O
any	TRULICITY.xml:S3:5998:3	O
other	TRULICITY.xml:S3:6002:5	O
antidiabetic	TRULICITY.xml:S3:6008:12	O
drug	TRULICITY.xml:S3:6021:4	O
.	TRULICITY.xml:S3:6025:1	O
